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Glioblastoma multiforme (GBM) is the most frequent and aggressive malignant tumor of the central 
nervous system in adults. Despite decades of experimentation to improve the outcome of patients 
with GBM, this type of neoplasm remains one of the most lethal human cancers.Therefore, the need 
to test different and new agents for efficacy and safety is urgent. Perifosine (PF) is a synthetic lipid 
analogue belonging to a relatively new class of structurally related antitumor agents: the 
alkylphospholipids (APLs). PF exhibits potent antineoplastic activity against a multitude of cancer 
cell lines and different tumor models and is currently being tested in phase II clinical trial against 
major human tumors. However, the effect of PF against gliomas is poorly investigated. PF can 
induce apoptosis and/or cell growth arrest in tumor cells, but the details of its molecular mechanism 
is still to be elucidated. To date, the Ser/Thr kinase Akt, which is a key regulator of multiple 
survival pathways, is considered as the most important molecular target of PF. 
However, PF can induce also Akt-independent effects and the contribution of Akt inhibition to the 
clinical activity of PF remains to be assessed. As other ALPs, PF may alter the structure and 
function of cell membranes directly by inducing a biophysical disturbance of cell membranes where 
it accumulates and/or indirectly by interfering with the metabolism and transport of membrane 
lipids. In particular, alterations in the properties of lipid rafts, ordered membrane lipid domains 
enriched in cholesterol and sphingolipids (SLs), could affect numerous signaling pathways crucial 
to cell survival and proliferation that are dependent on these structures. 
On these premises, the purpose of this study was to investigate the sensitivity of GBM cells to PF 
treatment and to provide a contribution to the understanding of its molecular mechanism by 
focusing on the ability of PF to target membrane lipid metabolism and content, and, as a 
consequence, membrane-related signaling pathways crucial in the regulation of cell demise. 
At first, we evaluated the effect of PF on cell survival in several human GBM cell lines. We 
demonstrated that in these cell lines PF inhibits cell viability in a dose-dependent manner and that 
its cytotoxic effects are not solely due to Akt inhibition. Furthermore, we found that in glioma cells 
PF maintains ERK in its phosphorylated/active state in a sustained manner over time. Treatment 
with the MAPK inhibitor PD98059 potentiates PF toxicity, and strongly reduces PF-induced LC3B-
II increase. This could thus represent a molecular mechanism for self-defense from PF, at least in 
part due to the induction of protective autophagy. Moreover, in cells exposed to PF we found a 
time-dependent increase in the number of giant and multinucleated cells with an irregular shape, 
these morphological changes resembling those described for mitotic catastrophe, suggesting that 
this could be the mechanism of PF-induced cells death, while apoptosis was undetectable. 
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Accumulating literature indicates that in several tumor cell lines PF inhibits the rate limiting step of 
phosphatidylcholine (PC) synthesis, which is catalyzed by CTP:phosphocholine 
cytidylyltransferase, and this was associated to cell death with still unclear mechanisms. 
Furthermore, PC is the donor of phosphocholine in the reaction catalyzed by the enzyme 
sphingomyelin synthase (SMS), so the inhibition of the PC biosynthesis may also affect the 
sphingomyelin (SM) biosynthesis from ceramide (Cer). We found that also in GBM cells PF affects 
PC biosynthesis. In addition, in our model PF inhibits SM biosynthesis by affecting SMS activity, 
and the reduced PC seems not to represent a limiting factor for SM synthesis. The decreased 
utilization of Cer for SM biosynthesis results in a modest increase of Cer, which can accumulate at 
the endoplasmic reticulum (ER). Therefore, both the increased Cer levels, both the inhibition of PC 
synthesis in the ER could trigger ER stress ultimately leading to cell death. However, it is known 
from literature that in our GBM cells model PF fails to provoke ER stress, suggesting that other 
aspects of membrane lipid homeostasis, such as that involved in membrane functionality, are most 
probably involved in PF-induced cell death. Indeed, PC is the most abundant phospholipid in 
eukaryotic cellular membranes, essential for new membrane formation. On the other hand, SM 
together with glycosphingolipids (GSLs) represent the major SLs of the plasma membrane, 
displaying an asymmetric or polarized distribution, and play important roles in the regulation of 
membrane fluidity and sub-domain structures involved in cell signaling. 
We demonstrated that PF affected the endogenous levels of phospholipids (PLs), inducing a 
decrease in the total PLs/protein ratio accompanied by a change in the PLs pattern. PF-treated cells 
were poorer in PC, SM, and phosphatidylserine (PS), and richer in phosphatidylethanolamine (PE). 
In addition, PF induces an about 60% increase of endogenous gangliosides content compared to 
untreated cells. 
The dramatic changes in PLs and SLs endogenous content induced by PF could significantly affect 
membrane composition and functionality, which in turn can be involved in the biological response 
of cells to PF treatment. Indeed, we found that the inhibition of SM synthesis mimicked and 
potentiate PF cytotoxic effects; in addition the inhibition of gangliosides biosynthesis reverses 
cytotoxic action of PF thus suggesting that increase of gangliosides content is essential for its 
cytotoxic action. 
In conclusion, PF treatment in GBM cells results in a complex network of effects where the 
alteration of the metabolism and content of membrane-lipid components (and maybe their related 
secondary messengers), seems to play a key role in determining cell death. 
This study indicates that PF is decisive in its target to fight GBM cells, this representing a critical 





1. HUMAN GLIOMA 
 
1.1 Overview of glioma features 
 
Central nervous system (CNS) malignancies are among the most devastating human tumors, given 
the central role of the brain in every aspect of bodily function (Louis et al., 2002). These cancers are 
often deadly, as conventional anti-tumor therapies have limited or no efficacy. The World Health 
Organization (WHO) recognized dozens of different types of CNS malignancies (Louis et al., 
2002). CNS neoplasms present unique features compared to all the other cancers. First of all, it is 
harder than for other tumors to distinguish between benign and malignant lesions. Indeed, some 
glial tumors show benign histological features (low mitotic index, cell uniformity and slow growth), 
but a clinically malignant behavior, infiltrating entire regions of the brain. Furthermore, the 
anatomical location of the tumor can result in severe neurological impairment, e.g. when an 
expanding benign tumor cause brain compression in critical functional portions of the brain. 
(Buckner et al., 2007; Louis et al., 2002; Vescovi et al., 2006). Among the CNS tumors, gliomas are 
the most frequent primary brain tumors in humans, accounting for 78% of malignant CNS 
neoplasms. They derive from glial cells or their precursors, and very rarely metastasize outside the 
CNS (Buckner et al., 2007; Wen and Kesari, 2008). Based on cell line derivation, differentiation, 
and on their morphological appearance, gliomas are divided in: astrocytoma, oligodendroglioma, 
oligoastrocytoma, ependymoma, and choroid plexus tumors (Behin et al., 2003; Rich and Bigner, 
2004).  Among them, astrocytomas show the highest incidence (75% of all gliomas) (Dolecek et al., 
2012). Astrocytomas are classified by the WHO into four prognostic grades, depending on their 
histological features: nuclear atypia, mitotic activity, microvascular proliferation, and necrosis 
(Behin et al., 2003). This grading system allows to identify, in order of increasing anaplasia, 
pilocytic astrocytoma (grade I), diffuse or fibrillary astrocytoma (grade II), anaplastic astrocytoma 
(Grade III), and glioblastoma multiforme (grade IV). Grade I and II tumors are considered with a 
low-grade of malignancy, while tumors belonging to the class III and IV are considered high-grade 
malignant gliomas (Behin et al., 2003). The IV grade astocytoma, glioblastoma multiforme (GBM), 
is the most frequent malignant primary brain tumor in adult and is one of the most lethal human 
cancers. Indeed, despite the use of the latest surgical, radiation, and chemotherapy treatments, 
patients with GBM have a poor prognosis, with a median survival of 12 to 15 months (Rich and 
Bigner, 2004; Wen and Kesari, 2008). GBMs are called “multiforme”, because these neoplasms 
show a high heterogenity, both interpatient and intratumor. Intrapatient heterogeneity is due to 
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GBM clinical presentation and its location into the brain that often prevent to completely resect this 
tumor. GBMs could be clinically subdivided in primary and secondary. The majority of them (> 
90%) seems to arise de novo (primary GBMs), since they are diagnosed without evidence of a 
previous lower-grade tumor. They usually occur in sixty-seventy years old patients, who have a 
very short clinical history (less than 3 months). A smaller fraction of GBMs may arise from lower 
grade gliomas, with subsequent progression to higher malignancy grades (secondary GBMs). In 
general, secondary GBMs develop in fifty-sixty years old patients, and the time of progression from 
lower to higher grade lesions ranges from months to decades (Miller and Perry, 2007; Rich and 
Bigner, 2004). Intratumor heterogeneity is characterized by: i) macroscopic heterogeneity, with 
region of necrosis and hemorrhage; ii) microscopic heterogeneity, with regions showing 
microvascular angiogenesis, pseudopalisading necrosis, and pleomorphic nuclei and cells; iii) 
genetic heterogeneity, with different deletions, amplifications, and point mutations that ultimately 
affect multiple signal transduction and metabolic pathways; iv) cellular heterogeneity, with an 
highly variable cellular composition, multiple (genetically distinct) subclones, and numerous non-
tumor cells that, in concert with tumor cells, create the GBM microenvironment, essential in cell-
cell interactions and signaling. It is recognized that among the different cells that form GBM tumor 
mass exist a subpopulation of cells with stem-like properties, called GBM stem-like cells (GSCs), 
which are essential both in GBM initiation and aggressiveness. It has been suggested that these cells 
derive from transformed neural stem cells, or glial progenitor cells, that escaped the mechanisms 
that control proliferation and programmed differentiation. These cells are mainly localized in the 
subventricular zone and dentate gyrus of the hippocampus. Notwithstanding, GSCs can give rise to 
tumor anywhere in the brain because of their proliferative and migratory potential. Stem cells are 
distinct from the bulk of the tumor, but they appear to be responsible not only for tumor initiation, 
but also for resistance of standard treatments, recurrence, metastasis, and, at last, poor patient 
outcome (Dick, 2008; Merlo, 2003; Wen and Kesari, 2008). According to another hypothesis, 
gliomas arise from dedifferentiated astrocytes: unspecific stimulation by growth factors, e.g. 
transitorily released during traumatic and inflammatory conditions, may induce genetic mutations 
converting a mature astrocyte that retain the ability to respond to these factors into a more immature 
state of proliferation and migration, giving rise to gliomas (Merlo, 2003). 
Notably, despite their multiple heterogeneity, different GBMs are morphologically 
indistinguishable and have the same clinical course, responding similarly to conventional therapy. 
On the other hand, targeted molecular therapies may give different results (Holland, 2000; Maher et 
al., 2001). GBM heterogeneity, especially regarding the existence of populations with different 
properties within the same tumor, is in line with the GCS model (Siebzehnrubl et al., 2011).  
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1.2 Altered signaling pathways in glioblastoma tumorigenesis 
 
Despite the mechanisms of GBM onset and progression have not been clarified yet, a greater 
knowledge of the aberrations of signaling pathways associated with GBM has led to a better 
understanding of GBM’s aggressive nature and to the discovery of new therapeutic targets (Charles 
et al., 2011). Indeed, despite GBMs are strikingly heterogeneous, common alterations in specific 
cellular signal transduction pathways and cellular functions are associated with most GBMs, and 
drive their aggressive behavior. Among them, there are key signaling pathways that control cellular 
proliferation, survival, differentiation, migration, angiogenesis, DNA repair, and apoptosis. The 
main signaling pathways altered in GBMs (Fig.1) include p53, tumor suppressor retinoblastoma 
(pRb), growth factors and growth factor receptors, PI3K (phosphatidylinositol 3-kinase)/Akt, and 
Ras-Raf-MAPK pathways (Furnari et al., 2007; Ichimura et al., 2004; Merlo, 2003; Rich and 
Bigner, 2004). 
 
p53 pathway  
 
The p53 pathway comprises the p53 protein itself, the regulatory proteins of p53, and the p53 target 
genes. p53 is a master regulator of the cellular response to genotoxic stresses such as UV and γ 
irradiation, DNA damage, defects in DNA methylation, inadequate nucleotide supply, inappropriate 
oncogene activation, hypoxia, and cytotoxic drugs. In these stressful conditions, p53, that is a short-
lived transcription factor, is upregulated and acts promoting the expression of both proteins that halt 
the cell cycle and proteins involved in DNA repair. If the amount of damage is beyond the cell’s 
capacity for repair, p53 facilitates the expression of proteins involved in apoptosis, inducing cell 
death. So, the p53 tumor suppressor prevents the propagation of cells with an impaired genome, a 
consequence of which might be tumor formation. Indeed, a deficient p53 pathway functioning leads 
to a greater tolerance of genomic instability, possibly resulting in widespread genomic alterations, 
which are frequently found in many cancer, among which malignant glioma. Loss of normal p53 
function has been linked to gliomagenesis. This hypothesis is strengthened by the increased 
incidence of gliomas in patients with Li-Fraumeni syndrome, a familial cancer-predisposition 
syndrome associated with germline p53 mutations. TP53 (the gene encoding p53) inactivating 
mutation or loss is frequent in childhood gliomas, low-grade gliomas, anaplastic astrocytomas, and 
secondary GBMs. On the other hand, mutations or amplifications in regulators of p53 levels and 
activity are more common in primary GBM. Indeed, the chromosomal region containing Human 
doubleminute 2 (HDM2; the human xenologue of mouse double-minute 2 MDM2), that is one of 
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p53 downstream gene targets and, maybe, its most important modulator, is amplified in about 10% 
of primary GBM. HDM2 inhibits p53 transcriptional activity by binding to the p53-transactivating 
domain, inducing nuclear export, or functions as an E3 ubiquitin ligase, facilitating ubiquitin-
mediated p53 degradation by proteasome. Furthermore, another p53 downstream gene target 
encoding p14
ARF
 protein, that negatively regulates  HDM2 ability to target p53 for degradation, is 
often deleted or methylated in malignant gliomas (Ichimura et al., 2004; Merlo, 2003). 
 
pRb pathway  
 
The retinoblastoma protein (pRb) is a major regulator of cell-cycle progression, regulating G1/S 
transition. In quiescent cells, pRB is in its hypophosphorylated state and blocks proliferation by 
binding and sequestering the E2F family of transcription factors, and thus preventing the 
transactivation of genes essential for progression through the G1/S restriction point. Under 
mitogenic stimulation, the MAPK cascade is activated and promotes the expression of CyclinDs 
(D1-D3) and their association with the cyclin-dependent kinases (CDK)4 or 6, as well as the 
degradation of the CDK2/CyclinE inhibitor p27
Kip1
. These activated Cyclin-CDK complexes 
phosphorylate pRb, causing release of sequestered E2F transcription factors, that in turn 
transactivate the genes required for cell cycle progression into S phase and for DNA synthesis. The 





, which act by inhibiting the binding of CyclinDs to CDK4/6 and by 
displacing p27
Kip1
, which in turn binds and inhibits CDK2. In gliomas unscheduled cell-cycle entry, 
that favor unrestricted cellular proliferation, is due to any of the following several genetic 
alterations: mutational inactivation of Rb1 (the gene encoding for pRb) itself or the CKIs, 
epigenetic down-regulation of CKIs levels, or amplification/overexpression of CDKs4/6 or of the 
CyclinDs. Alteration of pRB pathway effectors or inhibitors occurs in both primary and secondary 
GBMs in a mutually exclusive manner. In low-grade gliomas mutations of cell-cycle components 
are uncommon, but the transformation from low-grade to intermediate-grade glioma is frequently 
related to dysregulation of the pRb pathway, highlighting the importance of its inactivation in 
glioma progression (Ichimura et al., 2004; Merlo, 2003). 
 
Growth factor signaling 
 
Inappropriately active cellular proliferation is a typical feature of most advanced cancers, including 
malignant gliomas. The disruption of the pRb pathway abolishes restrictions to proliferation, but 
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growth factor pathways give the proliferative stimulus in most GBMs. In addition to cellular 
proliferation, growth-factor pathways regulate many other pro-tumorigenic cellular functions such 
as apoptotic resistance, motility, invasion, and neo-angiogenesis. Numerous growth factor pathways 
induce the GBM phenotype, including the pathways of epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), insulin-like growth factor-1 (IGF1), vascular endothelial growth 
factor (VEGF), and transforming growth factor-ß (TGF-ß). Specific molecular constituents define 
each growth factor pathway, but the activation mechanism and the phenotypic impact of the 
pathways in GBMs are similar. Usually, growth factor ligands bind specific cell-surface receptors, 
forming a signaling complex, inducing receptor phosphorylation and activation. After 
phosphorylation, the receptors undergo conformational changes that allow them to bind intracellular 
effectors in order to propagate the pathway signal. To halt growth-factor pathway activity, the 
receptors are rapidly inactivated, internalized and degraded. There are different mechanisms by 
which gliomas may activate receptor pathways: i) overexpression of ligand and/or receptor, leading 
to an autocrine loop when both ligands and receptors are overexpressed; ii) mutations of receptor, 
leading to its constitutive activity in the absence of ligand or to its increased response to ligand 
because of its altered stability; iii) mutations and/or altered expression of genes coding for 
intracellular messengers or for their regulators, leading to intracellular messengers activation 
(Miller and Perry, 2007). 
 
PI3K /Akt pathway 
 
The PI3K/Akt signaling pathway is frequently altered in GBMs, due to oncogenic alterations in key 
elements of the pathway or aberrations in its regulation. PI3Ks are a family of protein and lipid 
kinases. Different classes of PI3Ks have been identified. Among them, the class IA PI3K, which is 
activated by receptor tyrosine kinases (RTKs) and also by the small GTPase Ras, seems to play an 
important role in tumorigenesis. Class I PI3Ks are able to catalyze the phosphorylation of 
phosphoinositol (PI) on the inner leaflet of cell membrane, and in particular of phosphatidylinositol-
4,5-bisphosphate (PIP2), which is converted in phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 
acts as a second messenger and recruits the serine/threonine kinase Akt to the plasma membrane by 
binding to its pleckistrin homology (PH) domain. Membrane translocation induces Akt 
conformational changes enabling its activation through phosphorylation at the two amino acid 
residues T308 and S473 by phosphoinositide-dependent kinase (PDK) 1 and PDK 2, respectively. 
Once activated, Akt phosphorylates numerous targets starting a series of signaling cascades 
involved in diverse cellular functions. The PI3K/Akt pathway positively regulates survival 
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pathways, promotes cell proliferation, regulates lipids and glucose metabolisms, cell movements 
and vesicle trafficking. The PI3K/Akt pathway is negatively regulated by the lipid phosphatase 
PTEN, that converts PIP3 back to PIP2, counteracting PI3K activity. The PI3K/Akt pathway is one 
of the most frequently hyperactivated signaling pathways in GBM. Alterations in this pathway 
include overexpression and mutations of RTKs genes, inactivating mutations or deletions of PTEN 
tumor suppressor gene, and oncogenic mutations in ras genes. Aberrant activation of PI3K/Akt 
pathway results in uncontrolled cell growth, resistance to cytotoxic treatments, massive 
angiogenesis, and migration/invasiveness (Chakravarti et al., 2004; Furnari et al., 2007; Holand et 
al., 2011; Rich and Bigner, 2004). 
 
The Ras-Raf-MAPK pathway 
 
The MAPK pathway is a signaling cascade, evolutionarily conserved, that consist of a set of protein 
kinases that ultimately transduces signals from the cell membrane to the inner of the cell and 
modulates gene expression. The MAPK pathway plays a pivotal role in regulating many biological 
functions, such as cell proliferation, migration, survival, and differentiation. 
This pathway is constitutively active in many tumors. Importantly, MAPK pathway is altered in 
88% of adult GBMs. The Ras-Raf-MEK-ERK signaling pathway is hyperactive in GBMs owing to 
an inappropriate activation of its upstream regulators, such as RTKs and/or integrins. 
On the other hand, unlike most cancers, somatic mutations of the RAS and BRAF (a RAF kinase) 
genes are very rare in malignant gliomas. However, altered Ras-Raf pathway, beyond the somatic 
mutations, plays an important role in the GBMs biology. Indeed, all three RAF proteins (ARAF, 
BRAF, and RAF1) are frequently overexpressed in human malignant gliomas. In addition, it has 
been reported that gliomas carry extra copies of the wild-type BRAF gene and that a significant 
correlation exists between activated MAPK and BRAF copy number gains. It was also found that 
this gene copy number gain is prevalent in high-grade gliomas. 
Of relevance, genetic and tissue-specific gene transfer studies demonstrate that constraining normal 
astrocytes and neuronal progenitors to express oncogenic RAS and BRAF leads these type of cells 
to shift into malignant gliomas, showing a crucial role of Ras-Raf pathway alterations in 
gliomagenesis.  The abnormal activation of this pathway may also have a role in the sustainment of 
GBMs. Indeed, inhibition of Ras-Raf-MAPK pathway with different mechanisms (e.g. through 





Figure 1. Cellular pathways frequently altered in gliomas (Rich and Bigner, 2004). 
 
1.3 Glioblastoma treatment 
 
Despite the intense efforts of scientists, neurologists and neurosurgeons to develop effective 
therapeutic approaches to defeat GBM, this tumor is still among the most deadly types of human 
tumors (Clarke et al., 2010; Rich and Bigner, 2004). The GBMs are so difficult to treat mostly 
because of their location and their complex and heterogeneous biology (Holland, 2000; Mrugala, 
2013). One of the major challenges in therapy of these type of tumors is associated with brain 
parenchyma vulnerability. Indeed, intracranial tumors exhibit a complex interaction with normal 
brain parenchyma, which enormously complicates the use of conventional therapies and the 
development of new treatments, since even minimal disturbance to the neural cytoarchitecture or 
circuitry can lead to dramatic functional disturbances (Holland, 2000; Louis et al., 2002; Vescovi et 
al., 2006). Another obstacle for the treatment of GBM is the presence of the blood-brain barrier 
(BBB), which hinders most therapeutic drugs to reach tumor mass in adequate concentrations (de 
Vries et al., 2006). The current therapeutic strategies for GBMs consist in maximal surgical 
resection, when achievable, followed by radiotherapy and chemotherapy (Clarke et al., 2010; 
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Holland, 2000). Unfortunately, GBMs are characterized by high levels of cellular proliferation and 
diffuse invasion into neighboring brain structures, hindering total surgical extirpation of the tumor, 
which inevitably recurs (Holland, 2000; Mrugala, 2013). Specialized techniques such as 
intraoperative MRI (magnetic resonance imaging), MRI-guided neuronavigation, functional MRI 
(Asthagiri et al., 2007), fluorescence-guided surgery (Stummer et al., 2006), awake craniotomy, and 
electrocortical mapping have enhanced surgery safety and allowed greater surgical resection of the 
tumor mass. Moreover, surgical debulking alleviates mass effect-symptoms, furnishes tissue for 
histological diagnosis and molecular studies, and enables to safely administrate subsequent 
treatments, such as radiotherapy and/or chemotherapy (Buckner et al., 2007), that slightly 
ameliorate patient prognosis. For example, it has been shown that radiotherapy treatment increases 
patients survival from 3-4 months to 7-12 months (Walker et al., 1978). In this regard, innovative 
radiation treatments have been designed using multiple field techniques to deliver high doses of 
radiation to tumor, but not to normal brain tissue, therefore hopefully decreasing the damage caused 
by radiations in the healthy areas. More in detail, these new radiation-based approaches are: the 
fractionated radiotherapy, that exploit the differing radiosensitivities of normal tissues and 
neoplasms, the stereotactic radiosurgery, that deliver a high radiation dose in a single fraction to an 
image-defined target, and stereotactic radiotherapy, that combines fractionated radiotherapy to 
stereotactic radiosurgery (Buckner et al., 2007). As previously mentioned, the surgical resection and 
the radiotherapy are often accompanied to chemotherapy, that may enhance the effectiveness of 
surgery and radiation approaches, improving GBM patient survival (from 6 to 10% increase in the 
1-year survival rate) (Buckner et al., 2007; Fine et al., 1993; Stewart, 2002). However, many 
limitations are associated with chemotherapy, as chemotherapeutics’ ability to cross the BBB, 
determined by size and lipophilicity of molecules, integrity of BBB, and presence of an active 
efflux pumps. GBMs impair the BBB integrity both structurally and functionally, but not in a 
uniform manner. The loss of the BBB in general does not occur along the infiltrating edges of the 
tumor, so that chemotherapy drugs do not reach the entire tumor at an effective concentration (de 
Vries et al., 2006; Jain et al., 2007; Neuwelt et al., 2011). Different strategies exist to overcome this 
drug delivery problem: increase the dosage of some drugs, conjugate drugs to lipophilic moieties or 
other vectors, package drugs in carrier systems (liposomes, micelles and dendrimers), co-
administrate drugs with inhibitors of BBB drug-efflux transporters, and infuse drugs directly into 
the tumor by a catheter or implanted therapies consisting of therapy-infused reservoirs or matrices 
(convection enhanced delivery) (Laquintana et al., 2009).  
The most commonly used chemotherapy drug in the treatment of high-grade malignant gliomas is 
temozolomide, an oral alkylating agent with good penetration of the blood-brain barrier, which has 
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showed therapeutic benefit (Buckner et al., 2007). However, the outcome of the standard treatment 
remains poor. Therefore, a hard work has been made in the last decades to identify new therapeutic 
targets to develop effective strategies to treat this so devastating and deadly cancer. These novel 
promising approaches include: gene therapy, in order to transfer lethal genes to the tumor cells; the 
use of viruses able to infect the tumor cells and then kill them lytically; and therapies that entice the 
immune system to reject the tumor (Holland, 2000). In addition, in recent years it is emerging the 
awareness that a multi-targeted therapies are essential to treat and defeat GBM, due to its extremely 
complex and heterogeneous molecular biology. For this reason, the need to test different and new 




2.1 An overview of sphingolipids 
 
Sphingolipids (SLs) were discovered more than a century ago by J. L. W. Thudichum, while 
studying the chemical composition of the brain. He coined the term “sphingosine” (hence the root 
term “sphingo-”) to indicate the backbone of all SLs, based on the Greek mythological Sphinx, 
because of its enigmatic properties (van Echten-Deckert and Herget, 2006). SLs are ubiquitous and 
essential structural components of eukaryotic membranes. However, in the last 20 years, advances 
in biochemical and molecular research highlight a pivotal role of SLs as bioactive metabolites in 
regulating a wide range of crucial cellular processes such as cell growth, death, adhesion, migration, 
and senescence (Hannun and Obeid, 2008). SLs have also been reported to dynamically cluster with 
sterols to form lipid microdomains (membrane rafts), which have been suggested as critical 
platforms for cell signaling (Simons and Ikonen, 1997). Concerning their chemical structures, SLs 
are amphipatic molecules composed by a hydrophobic moiety (ceramide, Cer), that acts as 
membrane anchor, and a hydrophilic headgroup. Cer, the structural element common to all SLs, is 
constituted by a long-chain amino alcohol (sphingoid base), connected by an amide linkage to a 
fatty acid, generally with a long-chain (palmitic (C-16) or stearic (C-18) acid or longer, sometimes 
hydroxylated). The most common sphingoid base in humans is sphingosine (Sph), containing 18-20 
carbon atoms (C-18 or C-20) and a C4-C5 double bound in the trans-D-erythro conformation, 
which is essential for some of the bioactive roles in which Sph-based SLs are involved. A number 
of other sphingoid long-chain bases exist, e.g. C-18 and C-20 sphinganines, which lack the double 
bond, the less common phytosphingosine, which carries a hydroxyl group on C-4, and 
methylsphingosine with a methyl group at C-15 (Lahiri and Futerman, 2007; Tettamanti et al., 
2003). Cer is the central building block of all complex SLs, which are synthesized by addition of 
16 
 
polar molecules (representing the polar headgroup) to its primary alcoholic residue (Lahiri and 
Futerman, 2007). A large variety of polar headgroups could be attached to Cer, including charged, 
neutral, phosphorylated, or glycosylated moieties. For example, attachment of phosphocholine 
forms sphingomyelin (SM), whereas attachment of glucose or galactose leads to the generation of 
glucosylceramide (GlcCer) and galactosylceramide (GalCer) respectively, used as precursors for the 
synthesis of more complex glycosphingolipids (GSLs). GSLs are the most structurally diverse class 
of complex SLs, and are normally classified as acidic or neutral. The neutral GSLs include GlcCer 
and GalCer (cerebrosides), while acidic GSLs carry an oligosaccharide chain containing one or 
more sialic acid residues (gangliosides), sulphate moieties (sulphatides) or glucuronic acid. The 
oligosaccharide moiety of both neutral and acidic GSLs may contain up to 15-20 saccharidic units 
(rarely more), with the main sugars being glucose, galactose, fucose, N-acetylglucosamine, N-
acetylgalactosamine. In addition, an attachment of phosphate at the carbon in position 1 (C-1) of the 
sphingoid base (Sph) or Cer forms Sph-1-phosphate (S1P) and Cer-1-phosphate (C1P), respectively 
(Lahiri and Futerman, 2007; Tettamanti et al., 2003). Therefore, the complexity of SLs is based on 
three structural constituents: the sphingoid base, the fatty acid, and the head moiety, keeping in 
mind that at least five different sphingoid bases have been identified in mammalian cells, 20 species 
or more of fatty acid (differing in chain length, degree of saturation, and hydroxylation grade) can 
be attached to the sphingoid base, and more than 500 different saccharides structures have been 
characterized in GSLs. Despite some preference of specific components to associate in particular 
SLs (e.g., certain fatty acids are frequently found in certain GSLs), it is obvious that the number of 
potential combinations is nonetheless disconcerting. The reason for such a variety of SLs structures 
is not known. It is still unclear if each distinct SL or GSL structure has its own unique role or rather 
the combinatorial pattern of SLs and GSLs at any one time and their distribution (or segregation) 
over the plasma membrane surface define their roles. However, such complexity demands highly 
organized and complex mechanisms of regulation at both the biochemical and cellular levels, that 
for the most part are still to be clarified (Futerman and Hannun, 2004; Lahiri and Futerman, 2007). 
 
2.2 Sphingolipids and membrane lateral organization 
 
The bulk structure of biological membranes consists in a bilayer of amphipathic lipids. The creation 
of the lipid bilayer is a first level of ordered organization of the membrane and is a consequence of 
the aggregational properties of complex amphipathic membrane lipids (Sonnino and Prinetti, 2013). 
The fluid mosaic model for cellular membrane structure, proposed by Singer and Nicholson, 
introduced the concept that the glycerophospholipid bilayer is a two-dimensional fluid construct 
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that allows the lateral movement of membrane components (Singer and Nicolson, 1972). During the 
past decades, it has become clear that lipids are not only the building blocks contributing to the 
membrane basic organization, but they may play active roles in modulating specific membrane 
proteins such as receptors, carriers, pumps, and enzymes. Moreover, some of the lipid components 
undergo lateral phase separation and influence the membrane curvature, asymmetry and strain 
within the two lipids layers, creating therefore multiple levels of lateral order able to form 
membrane microdomains endowed by different compositions and functions (Sonnino and Prinetti, 
2010). In the late 1980s, a growing number of experimental findings collectively gave rise to the 
lipid domain hypothesis. The notion that different levels of order exist in biological membranes is 
now deeply rooted in cellular biology. Lipid domains are commonly defined as fluctuating 
nanoscale assemblies of SLs, cholesterol, and proteins that can be stabilized to coalesce, forming 
platforms that function in membrane signaling and trafficking and that consequently are involved in 
a great variety of cellular functions and biological events (Lingwood and Simons, 2010). SLs are 
ubiquitous membrane components, being present in different organelle membranes and particularly 
abundant in the plasma membrane, where SM and GSLs represent the major SLs (Hakomori, 1990). 
SLs are amphipathic molecules, which accounts for their tendency to aggregate into membranous 
structures, with an hydrophobic portion (constituted by Cer) embedded in the lipid core of 
biological membranes and a hydrophilic portion protruding in the extracellular milieu (Feizi, 1985). 
Differently from glycerolipids,  SLs, and GSLs in particular, exhibit molecular structure and 
conformational properties which give them a strong tendency to segregate within phospholipid 
bilayers, forming subsequently laterally separated phases characterized by reduced ﬂuidity and 
hydrocarbon chain mobility (Sonnino and Prinetti, 2010; Tettamanti et al., 2003). Indeed, the Cer 
backbone of SLs is a relatively rigid system and is characterized by the presence of the amide 
nitrogen, the carbonyl oxygen and the hydroxyl group positioned in proximity of the water/lipid 
interface of the bilayer, which confers to SLs to act both as donors and acceptors for the formation 
of hydrogen bonds (Pascher, 1976). The formation of a network of hydrogen bond at the water/lipid 
interface of the bilayer considerably stabilizes the SLs segregation in specific membrane areas: the 
lipid membrane domains, also defined as “SL-rich membrane domains” (Pascher, 1976).  
Furthermore, in the case of GSLs, the presence of the bulky oligosaccharide hydrophilic headgroup 
strongly favor phase separation and spontaneous membrane curvature, due to the geometrical 
properties of different GSL headgroups (Sonnino and Prinetti, 2010). It has also been proposed that 
phase separation of GSLs could be favored by the formation of carbohydrate-carbohydrate 
interactions, i.e. hydrogen bonds involving the GSL sugar head groups, even if data proving this are 
lacking (Brocca et al., 1998). However, the hydrophylic character of sugars and the necessity to 
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avoid repulsion between the negative charged oligosaccharide attract water, which could have a role 
in organizing a net of hydrogen bonds able to stabilized GSL clustering (Bach et al., 1982; Brocca 
et al., 1998; Cantu et al., 1990; Ha et al., 1989; Heatley and Scott, 1988). Moreover, membrane 
complex lipids, such as glycerophospholipids, are characterized by a highly heterogeneity in their 
fatty acid composition, such as bearing acyl chains with different number of carbon atoms and 
unsaturations (Sonnino and Prinetti, 2010). This high degree of unsaturation provides membrane 
fluidity, a characteristic that is fundamental for the functional properties of a biological membrane. 
Lipids, such as SLs, mostly characterized by the presence of long saturated acyl chains (that can be 
tightly packed in the hydrophobic core of a bilayer), have the tendency to segregate within 
phospholipid bilayers into more ordered phases (Prinetti et al., 2009). It was estimated that 
distribution in the ﬂuid phase of a phospholipid bilayer is inversely correlated with the acyl chain 
length and directly correlated with the degree of unsaturation (Palestini et al., 1995). Notably, SLs 
display an asymmetric distribution in biological membranes, being present essentially in the outer 
monolayer. This raises the question: how could ordered domains form in the inner leaflet? To 
answer this question, it was suggested that interdigitation of long chain fatty acid residues of 
complex membrane lipids might be responsible for the tethering of the internal leaﬂet to the 
external one, inﬂuencing events localized on the cytosolic side of the membrane (Chiantia and 
London, 2013). As mentioned before, segregation of membrane SLs is responsible for the creation 
of less ﬂuid membrane regions, where membrane-associated proteins can be conﬁned. Several 
classes of membrane-associated proteins display a strong preference for the association of lipid-rich 
membrane domains, e.g. glycanphosphoinositide-GPI-anchored proteins, or protein with a lipid 
modification such as myristoylation/palmitoylation and double palmitoylation, which target 
proteins to lipid domains. Transmembrane proteins are, in some cases, also concentrated in lipid 
rafts. Finally, peripheral proteins can be associated or recruited to lipid rafts, possibly indirectly via 
interactions with raft-resident proteins (Brown, 2006; Prinetti et al., 2009). The association with 
lipid domains can affect the functional properties of a membrane protein in different ways: (a) the 
association with lipid domains could represent a mechanism to facilitate the co-clustering of 
different membrane proteins or, conversely, the trapping of a protein within lipid rafts could prevent 
it from interacting with other proteins preferentially localized in ﬂuid membrane regions; (b) the 
association of a protein with a rigid membrane zone could induce protein conformational changes 
affecting its functional activity; (c) proteins confined in lipid domains have a higher probability to 
laterally interact with specific lipids that can modulate their activity. For example, it has been amply 
demonstrated that GSLs (in particular, gangliosides) can interact and modulate the activity of 
plasma membrane proteins, such as receptor tyrosine kinase, even if in most cases it is still unclear 
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the molecular aspects of GSL-protein interactions, underlying the modulatory effect of GSLs 
(Prinetti et al., 2009). The oligosaccharide chain of a GSL inserted in the plasma membrane could 
interact with a membrane protein via a) amino acid residues belonging to the extracellular loops of 
the protein, if the conformation of the polypeptide chain allows them to be sufﬁciently close to the 
membrane surface; b) sugar residues in the glycans of a glycosylated protein, if the dynamics of the 
protein oligosaccharide chain allows the correct orientation toward the cell surface; c) the 
hydrophilic portion to the anchor in the case of GPI-anchored proteins (that is surely located in 
proximity of the extracellular surface of the membrane) (Prinetti et al., 2009). 
Notably, GSLs present an oligosaccharide chain directly involved in processes of cell social 
behavior. Indeed, the hydrophilic component is able to provide recognition sites for external 
ligands/agents/cells, eliciting a series of molecular events controlling fundamental cell functions 
such as proliferation/arrest of proliferation, differentiation/apoptosis, embryogenesis, ageing.  
The list of receptor functions of GSLs is extensive. For example, gangliosides can act as toxin 
receptors: cholera toxin from Vibrio cholera, and Escherichia coli heat-labile enterotoxin bind to 
GM1 (Angstrom et al., 1994), and Shiga toxin from Shigella dysenteriae binds to Gb3 (Keusch et 
al., 1991). GSLs also mediate E selectin-dependent rolling and tethering (Schnaar, 2004), 9-O-
acetyl GD3 plays a role in neuronal motility (Mendez-Otero and Cavalcante, 2003), and a-GalCer 
acts as a ligand recognized by a special group of immune T cells, known as invariant NKT cells 
(Hayakawa et al., 2004). Cer is present in small amounts within cell membranes, as it functions 
primarily as an intermediate of complex SL metabolism and acts as a cell signaling mediator 
(Futerman and Hannun, 2004). However, in some circumstances, it plays an active role in 
membrane lateral organization and dynamics (Goni and Alonso, 2006, 2009; Staneva et al., 2008). 
For example, Cer can induce the coalescence of large plasma membrane domains, promoting the 
raft residing CD95/Fas death receptor clustering, and subsequently inducing apoptosis (Grassme et 
al., 2003). The increase of Cer at the membrane domain level can be relevant to different 
physiological processes. It can be induced, for example, by the action of signaling-related 
sphingomyelinases (SMases), contributing to the definition of signaling platforms (Staneva et al., 
2008). Furthermore, Cer formation may induce a displacement of cholesterol from membrane 
domains, affecting membrane cholesterol homeostasis and so the activity of cholesterol-bound 
proteins (Goni and Alonso, 2009; Staneva et al., 2008). Indeed, SLs have a restricted ability to 
shield the small polar groups of Cer and cholesterol from contact with water and so Cer and 
cholesterol compete in their association with lipid domains (Goni and Alonso, 2009; Staneva et al., 
2008). Finally, the formation of Cer-enriched microdomains can promote membrane vesiculation 
and vesicle budding. The Cer-mediated vesicles budding could have a role in the sorting of 
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subcellular membranes into different populations of intracellular vesicles. It has also been 
implicated in the ER-Golgi vesicular traffic of both SLs and proteins (Giussani et al., 2006; 
Trajkovic et al., 2008). 
 
2.3 Sphingolipid metabolism 
 
Common synthetic and catabolic pathways govern the metabolism and catabolism of SLs, 
regardless of the heterogeneity in their structures and functions (Adan-Gokbulut et al., 2013). 
Pathways of SL metabolism have a unique metabolic entry point, constituted by the reaction 
catalyzed by serine palmitoyl transferase (SPT), which forms the first SL in the de novo pathway, 
and a unique exit point, constituted by the reaction catalyzed by S1P lyase, which breaks down S1P 
into non-SL molecules. The numerous metabolic steps form a highly intricate network, connecting 
the metabolism of many SLs. In this network, Cer occupies a central position in SLs biosynthesis 
and catabolism (Hannun and Obeid, 2008). SLs can originate from both the de novo pathway 
(Fig.2) or through the hydrolysis of complex SLs. The first reactions of the de novo biosynthetic 
pathway are catalyzed by membrane-bound enzymes active at the cytosolic face of the endoplasmic 
reticulum (ER), leading to the formation of Cer. The de novo pathway begins with the condensation 
of the amino acid L-serine with palmitoyl-CoA (or, less frequently, stearoyl-CoA), catalyzed by the 
enzyme serine-palmitoyl (or -stearoyl) transferase, to give rise to 3-keto-dihydrosphingosine, which 
is subsequently reduced by a NADPH (H
+
)-dependent oxidoreductase, 3-ketosphinganine reductase, 
to produce dihydrosphingosine (sphinganine). Dihydroceramide synthase (sphinganine N-acyl 
transferase) next acylates dihydrosphingosine to form dihydroceramide (dhCer), using, as acyl 
donor, fatty acyl-CoAs. Dihydroceramide synthase is also able to catalyse the acylation of 
sphingosine (Gault et al., 2010). In mammalian cells, six different isoforms of dhCer synthase 
(dhCerS/CerS) have recently been identified, and are encoded by six different genes, formerly 
known as longevity assurance (LASS) genes. The proteins encoded by these genes show substrate 
preference for specific chain length fatty acyl CoAs and so are responsible for the fatty acid 
composition of Cer. For example, CerS1 is involved in the production of C-18Cer, while CerS5 and 
CerS6 preferentially catalyze the acylation of (dh)Sph with myristoyl-, palmitoyl-, and stearoyl-
CoA compared with very long-chain fatty acyl-CoAs. These enzymes share common biochemical 
features, such as their catalytic mechanism, their structure, and intracellular localization, whereas 
show unique tissue distribution and different biological properties. Indeed, they are differently 
involved in a wide range of processes as diverse as cancer and tumor suppression, in the response to 
chemotherapeutic drugs, in apoptosis, and in neurodegenerative diseases (Levy and Futerman, 
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2010; Pewzner-Jung et al., 2006). The major part of the dhCer pool is then desaturated at the 4,5 





O2), with formation of Cer (Michel and van Echten-Deckert, 1997). The neo-synthesized Cer 
reaches directly the PM or is used as common precursor for SM and GSLs biosynthesis. 
Intriguingly, despite the large number of known GSL structures, only glucose and galactose have 
been found to be directly attached to Cer leading to GlcCer and GalCer, respectively. GalCer is 
synthesized from Cer and UDP-galactose by the action of Cer galactosyltransferase (CerGalT), an 
enzyme that is expressed mostly in oligodendrocytes and Schwann cells, but also in neurons and 
astrocytes. CerGalT is localized in the ER with a luminal orientation of its catalytic site, so Cer 
should be translocated from the cytosolic side, where it is formed, to the luminal side of ER 
membrane to be galactosylated. GalCer is then transferred to the lumenal Golgi compartment, 
where it is submitted to either sulphation to form sulfatide, sialylation to form ganglioside GM4, or 
further galactosylation to form Gal2Cer, the precursor for a rather restricted number of gala-series 
GSLs. GalCer is most abundant in oligodendrocytes and Schwann cells. GalCer and its sulphated 
derivative sulfatide represent 30% of the total lipid content of myelin (the specialized plasma 
membranes of Schwann cells in the PNS and oligodendrocytes in the CNS) and are essential to 
confer rigidity and stability to the membranes, allowing a correct conduction of nerve impulses (van 
Echten-Deckert and Herget, 2006). GlcCer biosynthesis occurs on the cytosolic leaflet of the Golgi 
apparatus, from Cer and UDP-glucose, through a reaction catalyzed by GlcCer synthase (GCS) 
(Jeckel et al., 1992). Whereas a minor part of the neo-synthesized GlcCer can directly reach the 
plasma membrane (probably via vesicular system), most of the GlcCer is translocated by a flippase 
enzyme to the luminal side of the cis-Golgi compartment, where further glycosylations take place. 
The first glycosylation, catalysed by lactosyl-Cer synthase is galactosylation of GlcCer to 
lactosylceramide (LacCer), which is the common precursor for all GSL-series, except the gala-
family (see above). LacCer is sialosylated to GM3, GM3 to GD3, and GD3 to GT3, by the action of 
three sialyltransferases (SAT I, SAT II and SAT III), each recognizing specifically the acceptor 
substrate. GM3, GD3 and GT3, are the starting points for the “a-series”, “b-series” and “c-series” 
gangliosides, respectively. Along each series, non specific N-acetyl-galactosaminyltransferase, 
galactosyl-transferase and sialyl-transferase (SAT IV) introduce in sequence a residue of N-
acetylgalactosamine, galactose, and sialic acid, respectively, giving rise to more complex 
gangliosides. Further sialosylations can be accomplished by sialosyl-transferase V (SAT V). From 
LacCer a further series of GSLs (“o-series”) can originate from the sequential action of N-acetyl-
galactosaminyl-transferase, galactosyl-transferase and sialyl-transferase IV and V, producing GA2 
(asialo-GM2), GA1 (asialo-GM1), and gangliosides GM1b, GD1c and GD1α (Degroote et al., 2004; 
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Ichikawa and Hirabayashi, 1998; Tettamanti et al., 2003; van Echten-Deckert and Herget, 2006). 
Gangliosides are major components of neuronal membranes, where they constitute 10–12% of the 
total lipid content (20–25% in the outer membrane layer) (Tettamanti et al., 2003). As regard to SM, 
its biosynthesis occurs by transferring a phosphocholine headgroup from phosphatidylcholine to the 
primary alcoholic residue of Cer, through the action of SM synthases (SMS), thereby also 
generating diacylglycerol. SM represents approximately 10% of the lipids present in mammalian 
cells. Until now, two different enzymatic SMS isoforms have been identified: SMS1, localized in 
the luminal side of the cis/medial Golgi apparatus and SMS2, primarily localized to the plasma 
membrane (Hannun and Obeid, 2008; Tafesse et al., 2006). Experimental evidence revealed that the 
most of the de novo synthesis of SM (~ 90%) occurs in the Cis/medial Golgi, while only a minor 
part occurs at the plasma membrane level. It was suggested that SMS2, being localized at the 
plasma membrane, plays a role as regulator of SM and Cer levels for signalling pathways and signal 
transduction (Giussani et al., 2014). 
As Cer synthesis occurs in the ER and that of GlucCer, complex GSLs and most of the SM in the 
Golgi apparatus, Cer must travel from one compartment to the other. Due to its hydrophobic nature, 
Cer do not spontaneous transfer through the cytosol, but need facilitated mechanisms. The transport 
of Cer to the Golgi occurs either through the action of a lipid transfer protein (CERT), which 
specifically delivers Cer for SM synthesis, or through a vesicle‑mediated route. Vesicular transport 
delivers Cer mostly for the synthesis of GluCer, but also SM biosynthesis is partially dependent on 
the vesicular transport of a pool of Cer to SM synthase (Riboni et al., 2010).  Cer can also undergo 
phosphorylation of the hydroxyl group of C-1 by the Cer kinase (CK), forming Cer-1-phosphate 
(Cer1P) (Hannun and Obeid, 2008). The subcellular localization of this enzyme has not been fully 
defined yet, but it seems to be at the level of the plasma membrane, the Golgi apparatus, and the 
cytoplasm (Van Overloop et al., 2006).  
Intermediate and final products of sphingolipid biosynthesis reach the plasma membrane mostly via 
the vesicles following the exocytotic membrane flow (Riboni et al., 2010). 
An important point to be taken into account concerns the dynamic state of the plasma membrane. 
Non dividing cells are characterized by a high degree of membrane internalisation and recycling. 
They are estimated to internalize via endocytosis about half their plasma membrane per hour. In this 
process, membrane components (lipids and proteins) are, at least in part, degraded and 
resynthesized or recycling, in order to maintain the cell surface composition dynamically constant.  
Consequently, the turnover of SLs has to be rapid in order to correspond to the overall membrane 
turnover, as well as to assist the formation of sphingoid bioregulators (Tettamanti et al., 2003). 
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Membrane GSLs are constitutively degraded by a process involving endocytosis and the endo-
lysosomal district. The intralysosomal degradation proceeds by the action of soluble hydrolytic 
enzymes, the (exo)glycohydrolases, which sequentially cleave off individual sugar residues starting 
from the non-reducing end of their glycolipid substrates. These enzymes are assisted by effector 
protein molecules named “sphingolipid activator proteins (SAPs, or saposines)” and negatively 
charged lipids. All the enzymatic steps of the degradative process require an acidic pH inside the 
organelle, that is warranted into the late endosome/lysosome organelles by the action of a proton 
pump that brings H
+
 from the cytosol to the inside of the organelles. The sequence of sugar removal 
from gangliosides is as follows: (a) the lysosomal sialidase convert the multi-sialogangliosides into 
the corresponding mono-sialogangliosides GM1and GM2 (which are resistant to this enzyme), or 
LacCer (from GM3); (b) galactose is removed from GM1 by a β-galactosidase (in the presence of 
either the GM2-AP or SAP-B) to form GM2; from GM2 the N-acetyl-galactosamine residue is split 
off to produce GM3 by the action of β-N-acetyl-hexosaminidase, which requires GM2-AP, an 
activator that is essential for the in vivo degradation of the GM2 gangliosides; (c) in some cells and 
animals, specific sialidases (GM1- and GM2-sialidase) remove sialic acid from GM1 and GM2, 
producing the corresponding a-sialo derivatives GA1 and GA2. GA1 and GA2 are then converted to 
LacCer by the action of β-galactosidase and β-N-acetyl-hexosaminidase or only β-N-acetyl-
hexonaminidase; (d) finally, a β-galactosidase (in the presence of either SAP-B or -C) and a β-
glucosidase act in sequence to degraded LacCer into Cer. The final products of degradation 
(individual monosaccharides, long chain bases, fatty acids), as well as intermediate by-products (for 
instance, LacCer, GlcCer and Cer) can leave the late endosome/lysosome and enter in the cytosol, 
where they can be “re-used” in biosynthetic pathway of SLs (“salvage pathway”) or can be further 
degraded (Tettamanti et al., 2003). As regard Cer and SM, both lysosomal and non-lysosomal 
degradation steps are known, which apparently do not need the assistance of an activator protein. 
SM is catabolized by the action of the enzyme sphingomyelinase (SMase), which hydrolyze the SM 
phosphodiester bond, with the consequent formation of Cer and phosphocholine. Three isoforms of 
SMase (acidic, neutral, and alkaline) have been identified and distinguished, according to their 
subcellular localization and the optimum pH of activity. Different enzymatic isoforms of acidic 
SMase exist and are localized in different cellular and extracellular compartments. Indeed, acidic 
SMase can reside in the lysosomal compartment, be secreted, or be in close association with the 
outer leaflet of the PM, where it can form Cer-rich platforms (Schissel et al., 1998; Stancevic and 
Kolesnick, 2010; Tabas, 1999). The neutral SMase (N-SMase) has distinct subcellular locations, 
including the inner leaflet of the plasma membrane, the ER, the Golgi, and even the nucleus (Clarke 
et al., 2006; Marchesini and Hannun, 2004). The alkaline SMase is mostly expressed in the 
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intestinal tract and in the bile, and is involved in SM digestion (Duan, 2006). Cer are also produced 
by dephosphorylation of Cer1P by lipid phosphatase(s). Cer can be catabolized by the action of 
specific a ceramidases (CDases), which hydrolytically cleave the N-acyl linkage of Cer to form 
sphingosine (Sph) and free fatty acid. Three isoforms of CDases, with different optimum pH and 
subcellular localizations, have been identified: acidic, neutral and alkaline CDases, which are 
located at the plasma membrane, lysosome, and ER/Golgi complex, respectively (Mao and Obeid, 
2008). Cer-derived Sph can be recycled or undergo phosphorylation in position C1 with the 
production of S1P by the action of Sph kinases (SKs). Two mammalian isozymes, which are known 
as SK1 and SK2, have been characterized. SK1 is predominantly cytosolic (Wattenberg et al., 2006) 
and SK2 is cytosolic and also associated with the nucleus (Igarashi et al., 2003). S1P can be 
irreversibly catabolized into hexadecenal and phosphoethanolamine by the action of S1P lyase 
(located on the ER-cytosolic side) in the final step of SL catabolism (Serra and Saba, 2010). 
Alternately, S1P can also be dephosphorylated back to Sph by the action of either S1P specific 
phosphatases, or non-specific lipid phosphate phosphatases (Le Stunff et al., 2007; Le Stunff et al., 
2002; Pyne et al., 2009). Notably, Sph origin is exclusively catabolic, since it only derives from SLs 
degradation (Sandhoff and Kolter, 1996). Sph can be recycled for SL formation via a recycling or 
salvage pathway (Hannun and Obeid, 2008). Indeed, Sph can reach the ER where it is N-acylated to 
regenerate Cer that can be used for the biosynthesis of complex SLs. The Sph recycling process 
provides an energy advantage to cells. It has been shown that in different cell types, such as cells of 





Figure 2. Schematic representation of SLs metabolism. SLs synthesized in the ER are in green, and those synthesized in 
the Golgi apparatus are in red. Enzymes are shown in italics, with those that reside in the ER in black and those that 
reside in the Golgi apparatus in blue. GalNacT, N-acetylgalactosamine transferase; GalT, galactosyltransferase; SAT, 
sialyl transferase (Lahiri and Futerman, 2007). 
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3. ANTITUMOR ALKYLPHOPSHOLIPIDS 
 
3.1 An overview of antitumor Alkylphospholipids 
 
Alkylphopsholipids (APLs) are lipid analogues that were first synthesized as potential immune 
modulators in the late 1960s, based on lysophosphatidylcholine (lysoPC) structure (Eibl et al., 
1967). Soon after, their role as antitumor agents was discovered (Eibl and Unger, 1990). At the 
beginning of their synthesis, the ester linkages at C1 and C2 of the glycerol backbone of lysoPC 
were replaced by ether bonds in order to yield metabolically stable analogs (van Blitterswijk and 
Verheij, 2013). Among this first generation of APLs, there is Edelfosine, which contain also a 
methyl group linked through an ether bond at the C2 position. Many other APLs were subsequently 
synthesize as promising anticancer agents, modifying Edelfosine chemical structure with the aim to 
improve metabolic stability and therapeutic potency. Although conventionally these compounds are 
collectively called APLs, formally they are divided in two classes: alkyl-lysophospholipids, which 
maintain the glycerol backbone, and alkyl-phospholipids, which are characterized by the lack of the 
glycerol backbone and by the alkyl chain esterified directly to the phosphobase (Fig. 3).  Edelfosine 
and its thio-ether derivative Ilmofosine belong to the first class, while Miltefosine, Perifosine (PF), 
Erucylphosphocholine, and Erufosine belong to the second class (van Blitterswijk and Verheij, 
2013). Edelfosine and Ilmofosine, both first generation of APLs, show a relatively low stability 
compared to the APLs of the second class, due to the glycerol backbone (Fensterle et al., 2014). 
Although Edelfosine has shown selective cytotoxicity toward tumor cells both in vitro (Mollinedo 
et al., 2010; Mollinedo et al., 1997; Ruiter et al., 1999; Runge et al., 1980) and in preclinical models 
(Berdel et al., 1980; Berger et al., 1984; Mollinedo et al., 1997; Scherf et al., 1987; Tarnowski et al., 
1978), it has proven disappointing in clinical trials. In fact, the clinical use of Edelfosine at the 
moment is substantially restricted to the bone marrow purging ex vivo in acute leukemia patients 
(Vogler et al., 1996; Vogler et al., 1992). Similarly, Ilmofosine has displayed anti-cancer activity 
both in vitro and in vivo against different type of cancers, but results from clinical trials have been 
discouraging (Giantonio et al., 2004; Herrmann et al., 1990; Woolley et al., 1996). Miltefosine, the 
minimal structural requirement for the anti-tumor activity of APLs, is a second generation APL that 
has shown potent antitumor activity in vitro such as in some tumor models, and is currently used for 
the topical treatment of cutaneous breast cancer metastases (Leonard et al., 2001) and cutaneous 
lymphomas (Dumontet et al., 2006). Because of its hemolytic effect when injected intravenously, it 
can only be administered orally or topically (Kotting et al., 1992). Unluckily, dose limiting 
toxicities impeded its further development as an oral anti-cancer agent. The third generation APLs, 
Perifosine, Erucylphosphocholine, and Erufosine, were synthesized as variants of Miltefosine. In 
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Perifosine, the choline headgroup of Miltefosine is replaced by a heterocyclic methylated piperidine 
moiety, giving rise to a markedly stable molecule, with fewer gastrointestinal side effects (Hilgard 
et al., 1997; Vink et al., 2005). Perifosine has turned out to be an orally-active agent with potent 
antineoplastic activity and is currently tested in clinical trials for the treatment of a wide variety of 
cancer types, as we will talk about extensively later on (Fensterle et al., 2014). 
Erucylphosphocholine consists of a carbon chain longer than Miltefosine and presents a cis-13,14 
double bond. Erufosine differs from Erucylphosphocholine only by the introduction of a methyl 
residue in the choline headgroup, making this agent more soluble in aqueous solutions. These 
structural modifications eliminate hemolytic- and myelotoxicity due to the formation of lamellar 
instead of micellar structures in aqueous solutions, allowing these compounds to be administrated 
intravenously, reducing gastrointestinal toxicity and reaching a higher plasma concentrations in 
vivo (van Blitterswijk and Verheij, 2013). Preclinical studies, both in vitro and in vivo, have shown 
that these two synthetic lipids are promising therapeutic agents against brain tumor. Indeed, they are 
effective even at relatively low doses and, compared to the others APLs, have a greater ability to 
efficiently cross the blood brain barrier and to accumulate in brain tissue (Erdlenbruch et al., 1999; 
Erdlenbruch et al., 1998; Henke et al., 2009). At the moment, there aren’t clinical data available on 
these compounds. 
 
Figure 3. Chemical structures of LysoPC, Edelfosine, Ilmofosine, Miltefosine, Perifosine, Erucylohosphocholine, and 




Recently, a novel class of APLs that displays significant anticancer activity has been synthesized 
with the primary aim to improve solubility in aqueous solutions. This is the class of glycosylated 
antitumor ether lipids (GAELs), the fourth generation of APLs, that are in turn divided into two 
main subclasses: glycosidated phospholipids and non-phosphorous GAELs. Glycosylated 
phospholipids contain carbohydrates or carbohydrate-related molecules at the chemical lead of a 
biologically active phospholipid, the platelet-activating factor (PAF), whose chemical structure 
exhibits similarity to Edelfosine and was identified ten years after Edelfosine synthesis (Fig. 4). 
Inositol-C2-platelet-activating factor is the most potent anticancer agent of this class. Non-
phosphorous GAELs have a carbohydrate moiety in place of the phosphobase present in APLs. 
Among this group, there is ET-16-OCH3-Gln, the most effective compound of this new family to 
date. The antitumor activities showed both in vitro and in vivo make these compounds promising 
treatments to test in clinical trials (Arthur and Bittman, 2014; Semini et al., 2014). 
 
 
Figure 4. Chemical structures of PAF, Ino-C2-PAF, and ET-16-OCH3-Gln (modified image from(Mollinedo, 2014). 
 
3.2 Alkylphospholipids in cancer: mechanisms of action, modes of internalization and cellular 
resistance 
 
The mechanisms of action of APLs are different from that of standard chemotherapeutic drugs. 
Indeed, APLs do not interact directly with the DNA, but rather target the cell membranes where 
they accumulate, due to their aliphatic character and metabolic stability. At high concentrations, 
they would cause cell lysis, owing to their detergent properties. Nevertheless, at lower clinically 
achieved concentrations, they have an impact on membrane lipid composition and lipid metabolic 
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processes, affecting lipid-based signal transduction pathways which can lead to cellular stress, cell 
growth inhibition and/or apoptosis. APLs show higher specificity towards metabolically 
active/proliferating cells, like tumor cells, than towards quiescent normal cells (van Blitterswijk and 
Verheij, 2013). A wide variety of mechanisms have been proposed to clarify the actions of these 
compounds. However, it is still unclear what molecular target play a crucial role for their ability to 
induce cell growth arrest or cell death and may well differ according to cell type and the type of 
ALP (van Blitterswijk and Verheij, 2013). Extensive evidence suggests that the inhibition of 
phosphatidylcholine (PC) biosynthesis by APLs is a key event determining inhibition of cell 
proliferation and/or apoptosis in different tumor cell lines. Indeed, PC is the most abundant 
phospholipid in eukaryotic cellular membranes, not only essential for new membrane formation, but 
also involved in cell signaling processes. APLs inhibit the rate-limiting enzyme for PC biosynthesis, 
CTP:phosphocholine cytidylyltransferase (CT). This enzyme resides in the nucleus and cytoplasmic 
compartments, where it is inactive, and becomes active when it is bound to membranes. APLs 
prevent CT translocation from the cytosol to the membrane of the ER. In particular, it has been 
suggested that APLs, that are type I lipids, impair the stored curvature elastic energy of the 
membrane, leading to membrane expansion with the consequent reduction in the partitioning of CT 
in the membrane (Dymond et al., 2008). How the inhibition of PC synthesis initiates apoptosis is 
still unclear. One possibility is that the shortage of PC inhibits the SM biosynthesis catalyzed by 
SMS from PC and Cer, leading to an accumulation of Cer, which is a pro-death molecule (Morad 
and Cabot, 2013). Another possibility is that the inhibition of PC synthesis in the ER triggers ER 
stress and/or oxidative stress, e.g. inducing the ER stress-related pro-apoptotic transcription factor 
CHOP/GADD153, which subsequently lead to the activation of the apoptotic machinery (van 
Blitterswijk and Verheij, 2013). Other authors, however, consider that the inhibition of PC synthesis 
is not a crucial event, but only plays a minor role in APLs-induced cell death (van der Sanden et al., 
2004). Different studies have demonstrated that in several tumor cell lines APLs are enriched in 
membrane microdomains (also known as lipid raft) and that their antineoplastic activity is closely 
related with these structures. It has been proposed that their mode of action might be related with 
their ability to induce alterations in lipid composition and/or biophysical properties of lipid rafts 
(Castro et al., 2013; Marco et al., 2014; van Blitterswijk and Verheij, 2013).  Lipid rafts are specific 
membrane microdomains enriched in cholesterol and saturated SLs that are more ordered than the 
bulk membrane (Lingwood and Simons, 2010). Growing evidence suggests that lipid rafts, with 
their unique lipid composition, provide specialized lipid environments, which regulate the sorting of 
membrane proteins, and the recruitment and the concentration of signaling molecules at the plasma 
membrane level, functioning in membrane signaling and trafficking (Coskun and Simons, 2010; 
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Simons and Gerl, 2010). Within this context, it has been established that cholesterol is crucial in 
stabilizing different types of lipid microdomains (Bakht et al., 2007; Pike, 2009) and, coherently, it 
has also been shown that enrichment of the membrane with cholesterol destabilizes membrane rafts 
(Marco et al., 2014). Interestingly, APLs could induce a deregulation of cholesterol homeostasis. In 
particular, APLs impair the non-vesicular transport of cholesterol from the plasma membrane to the 
ER, inhibiting cholesterol esterification. This causes a significant cholesterogenic response and so 
an increase in the de novo synthesis and uptake of cholesterol, that ultimately leads to an 
accumulation of free cholesterol within the cell and, in particular, in membrane microdomains such 
as lipid rafts. So, it has been suggested that the alteration of cholesterol homeostasis induced by 
APLs, concomitant to the reduction in PC and SM biosyntheses, leads to a modification in the 
cholesterol/choline-bearing phospholipids ratio, affecting lipid rafts composition and so their 
integrity and functionality. The APLs-induced disturbance of the cell native membrane structure 
may lead to alterations of signaling pathways critical for cell survival and growth (Gajate and 
Mollinedo, 2014; Marco et al., 2014). Mollinedo and coworkers have shown that in several 
hematologic cancer cells APLs (Edelfosine in particular) induce apoptosis by the coaggregation of 
Fas/CD95 death receptor with lipid rafts, independent of its natural ligand FasL, driving the 
formation of the so called DISC complex (death-inducing signaling complex), together with the 
recruitment into lipid rafts of downstream signaling molecules. The authors coined the term 
CASMER (cluster of apoptotic signaling molecule-enriched rafts) to indicate this novel raft-based 
supramolecular entity, which acts as death-promoting scaffolds facilitating the triggering of a potent 
cell death response (Gajate and Mollinedo, 2014). The action of APLs on lipid rafts does not only 
favor cell death pathways, but also alters survival, adhesion and migration signal transduction 
pathways (Mollinedo, 2014). It has also been shown that APLs may accumulate in mitochondria, 
causing their swelling and destabilization. Mitochondria are crucial components of cell’s apoptosis 
machinery. So, APLs may initiate apoptosis altering mitochondrial membranes (Kuerschner et al., 
2012; Mollinedo et al., 2011). 
To affect their multiple cellular targets, the APLs have to be internalized into the cells. Essentially 
two modes of internalization are possible: (a) by lipid rafts-mediated endocytosis and (b) by trans-
bilayer movement from the outer to the inner leaﬂet of the plasma membrane. The last occurs either 
via spontaneous ﬂipping (slow because energetically unfavorable), or through an ATP-dependent 
lipid translocator. It has long been difficult to determine which of the two mechanisms is most 
relevant and it seems to depend on the cell types (van Blitterswijk and Verheij, 2013). Indeed, 
lymphoid cells internalize ALPs predominantly via lipid rafts-mediated endocytosis, while 
carcinoma cells utilize a lipid translocator/ﬂippase (Munoz-Martinez et al., 2008; Vink et al., 2007). 
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Alteration of the mechanisms of APLs internalization can cause APL-mediated apoptosis resistance. 
In carcinoma cells, e.g., APLs uptake occurs through a transmembrane phopsholipids flippase P4-
ATPase ATP8B1, which function in complex with a CDC50a subunit. The CDC50a subunit is not 
only necessary for ATP8B1 functionality, but also for its export from the ER to the plasma 
membrane. Accordingly, it has been shown that in PF-resistant carcinoma cells a defect in CDC50a 
trafﬁcking and plasma membrane insertion is the underlying mechanism of PF-resistance (Munoz-
Martinez et al., 2010). On the other hand, S49 mouse lymphoma cells made resistant to ALP 
(Edelfosine), S49
AR
 cells, showed a complete downregulation of SMS1 and consequently were not 
able to synthesize SM (Van der Luit et al., 2007a), a major component of lipid rafts, where APLs 
have been shown to accumulate (van Blitterswijk and Verheij, 2013). These cells had acquired 
cross-resistance to other ALPs (van der Luit et al., 2002; Van der Luit et al., 2007a; van der Luit et 
al., 2007b; Vink et al., 2007) as well as to DNA damage and Fas/CD95 ligation (Alderliesten et al., 
2011; van Blitterswijk et al., 2010). Accordingly, S49
AR
 cells exhibited a decreased Fas/CD95 
expression (van Blitterswijk et al., 2010), a sustained ERK/Akt activity (Alderliesten et al., 2011), 
and an abrogated raft-mediated ALP internalization (van der Luit et al., 2002). SM synthesis by 
SMS1 in the Golgi is essential for new lipid raft formation and for the anterograde (from the Golgi 
towards the plasma membrane) and the retrograde (from the plasma membrane to the Golgi) 
vesicular trafﬁcking (Ikonen, 2001; Tafesse et al., 2006; van Blitterswijk et al., 2003). SMS1 
deﬁciency would prevent ALP internalization, blocking raft endocytosis along the retrograde route, 
and so make cells resistant. Interestingly, in parental S49 cells downregulation of SMS1 by siRNA 
was enough to induce the above-mentioned cross-resistance (Van der Luit et al., 2007a; van der 
Luit et al., 2007b). It was also found that S49
AR
 cells lacked the PI(3,4,5)P3 phosphatase SHIP-1 
[SH2 (Src homology 2)-domain-containing inositol phosphatase 1], a known regulator of the Akt 
survival pathway (Alderliesten et al., 2011). It was suggested that SHIP-1 cooperate with SMS to 
regulate apoptosis sensitivity of lymphoma cells to ALPs, as well as to other apoptotic stimuli. 
Indeed, re-sensitization of the S49
AR
 cells, by prolonged culturing in the absence of ALP, restored 
SHIP-1 expression as well as phosphoinositide and SM levels. Knockdown of SHIP-1 in parental 
cells mimicked the S49
AR
 phenotype in terms of apoptosis cross-resistance, SM deﬁciency and 
altered phosphoinositide levels (Alderliesten et al., 2011). So, the sensitivity to ALPs could be very 
different among several cancer cell types and depend on the different contributions of pro- and anti-
apoptotic mediators, as well as on the rate of cellular ALPs uptake, which, in turn, has been shown 
to be closely related to the extent of cellular proliferative activity and associated metabolic (lipid) 
turnover (van Blitterswijk and Verheij, 2013). As regards their clinical use, APLs are among the 
most promising candidates to combine with other anticancer therapy. These compounds have the 
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advantage of possessing a unique mechanism of action, acting at the cell membranes levels rather 
than on the DNA, as many conventional therapies. So, it is conceivable that a combination of drugs 
with different mechanism of action may lead to additive or even synergistic therapeutic effects and 
may also overcome chemo- and radio-resistance of tumor cells. The most studied and most 




PF is a third generation APL, composed of a heterocyclic piperidine group connected by a 
phosphate group to a long alkyl chain. PF exhibited a potent antineoplastic activity against a wide 
range of tumor cell types in vitro and a high specificity against cancer cells, as it has been shown in 
pre-clinical and clinical studies (Fensterle et al., 2014; van Blitterswijk and Verheij, 2013; Vink et 
al., 2005). The PF-enrichment in tumor tissues might be mediated by a selective enrichment in 
cholesterol rich lipid rafts of tumor cells (Fensterle et al., 2014). PF is both a cytostatic and a 
cytotoxic agent (Fensterle et al., 2014). Compared to the other previously synthesized  APLs, this 
novel oral APL showed increased stability and, consequently, a prolonged plasma half-life in vivo 
(Hilgard et al., 1997; Vink et al., 2005). The long plasma half-life and the substantial accumulation 
of PF in tumor tissues allowed clinical dosing regimens with moderate oral doses, resulting in 
limited toxicity. The favorable toxicity profile of PF is a fundamental prerequisite for its use in 
combination with other anticancer drugs (Gills and Dennis, 2009). PF was tested in a multitude of 
clinical studies both as single agent and in combination with other agents (Gills and Dennis, 2009; 
Vink et al., 2005). Clinical trials of PF as a single agent on recurrent prostate cancer, 
adenocarcinomas, and melanomas have been disappointing (Vink et al., 2005), while on renal cell 
carcinoma and neuroblastoma they have shown promise (Porta and Figlin, 2009); Belcher et al., 
2010). However, PF anticancer activity has been most successfully exploited in combination with 
other anti-cancer regimens. Combination trials in multiple myeloma and colorectal cancer have 
reached Phase III, but recently these studies failed to demonstrate clinical activity with the low dose 
PF scheme in patients with metastatic colorectal cancer and relapsed multiple myeloma in 
combination with capecitabine and bortezomib, respectively (Fensterle et al., 2014). PF has 
different targets which have been linked to its anticancer activity (Fig. 5). To date, the Ser/Thr 
kinase Akt, which is a key regulator of multiple survival pathways, is considered as the most 
important molecular target of PF (Fensterle et al., 2014; van Blitterswijk and Verheij, 2013). Akt is 
a central member of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, which is 
aberrantly active in most human malignancies and positively regulates cell growth, proliferation, 
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and survival. Furthermore, PI3K/Akt pathway activation has been associated to therapeutic 
resistance. So, the Akt pathway is assumed to be one of the most attractive targets for tumor therapy 
(Fu et al., 2009; LoPiccolo et al., 2008). The mechanism by which PF inhibits Akt is very different 
from that of previous ATP-competitive and allosteric Akt-inhibitors. PF interferes with the normal 
function of the lipid-binding pleckstrin homology (PH) domain of Akt. PF may do so in two 
different ways: (1) by disrupting membrane microdomains crucial to Akt activation and (2) by 
binding directly to the PH domain of Akt, thereby displacing the natural PI(3,4)P2 and PI(3,4,5)P3 
ligands. Since PF prevents the Akt recruitment to the plasma membrane, Akt is no longer able to 
adopt the favorable conformation for its phosphorylation/activation and to activate its downstream 
effectors (Bellacosa et al., 1998; Dineva et al., 2012; Gills and Dennis, 2009; Hennessy et al., 2007; 
Kondapaka et al., 2003; van Blitterswijk and Verheij, 2013). Coherently, overexpression of 
myristoylated Akt that is constitutively active (it does not require PI(3,4)P2 and PI(3,4,5)P3 bindings 
for the plasma membrane recruitment) abolished PF-mediated decrease of Akt phosphorylation and 
cell growth inhibition/apoptosis (Gills and Dennis, 2009; Hennessy et al., 2007; Kondapaka et al., 
2003; van Blitterswijk and Verheij, 2013). PF-mediated Akt inhibition may also modulate the 
activity of many important downstream targets. As an example, PF induces cell cycle arrest through 
the up-regulation of P21
WAF1/CIP1
 in a p53 independent manner and the loss of cyclin-dependent 
kinase 2 (cdk2) activity (Kondapaka et al., 2003; Patel et al., 2002). Furthermore, Fu et al. showed  
that PF in human lung cancer cell lines, besides inhibiting Akt, inhibited mTOR signaling (Fu et al., 
2009). In particular, PF hindered the assembly of both mTOR/raptor and mTOR/rictor complexes 
by promoting the degradation of major elements in the mTOR axis, including mTOR, raptor and 
rictor. As a consequence, PF induced autophagy in addition to apoptosis. The combination of PF 
with lysosomal inhibitors enhances apoptosis induced by PF as well as its anticancer efficacy in 
vivo, suggesting that PF-induced autophagy protects cells from undergoing apoptosis (Fu et al., 
2009; Sun, 2010). It was also shown that PF, through Akt-inhibition, prevent the inhibitory 
phosphorylation of GSK3β which, in turn, modulates the activity of the Wnt signaling pathway 
(Floryk and Thompson, 2008; Korkaya et al., 2009). Finally, in waldenstroem macroglobulaemia 
cells, PF inhibited Akt and NF-kB, which can be activated by Akt via the Akt-IKK-IkB- NF-kB 
axis. Akt is a validated target of PF at pharmacological relevant levels, since Akt inhibition by PF 
has been confirmed in a wide variety of tumor cell lines as well as in vivo in xenograft models of 
different type of cancer (Fensterle et al., 2014). In particular, the most persuasive preclinical study 
relating PF-induced Akt inhibition with anticancer potency was performed by Hennessy et al. In 
this study, the authors confirmed that in different tumor cells PF inhibit Akt activation by hindering 
its translocation to the plasma cell membrane and demonstrated that in several prostate, breast and 
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ovarian cancer xenograft models, growth inhibition was correlated with the extend of Akt inhibition 
induced by PF administered on different schedules. They also demonstrated that cell lines resistant 
to PF did not show Akt inhibition in vivo (Hennessy et al., 2007). However, PF exerts also Akt-
independent effects and the importance of Akt inhibition for its anticancer activity would still be an 
open question (Gills and Dennis, 2009). Indeed, although many preclinical studies have reported 
Akt inhibition by PF, only few clinical trials with PF have evaluated Akt status in patient tissues, 
rendering difficult to make assumptions on the contribution of Akt to its clinical efficacy. As 
discussed extensively as regards the mechanisms of action of APLs in general, PF, in addition to 
targeting Akt, interferes with the biosynthesis of membrane lipids, e.g. inhibiting PC biosynthesis 
(van Blitterswijk and Verheij, 2008), and altering the homeostasis and transport of cholesterol 
(Carrasco et al., 2010; Jimenez-Lopez et al., 2010; Rios-Marco et al., 2013). Furthermore, PF might 
disturb membranes both acting on the metabolism and transport of membrane lipids and/or directly 
inducing a biophysical disturbance of cell membranes in which it is inserted, consequently affecting 
membrane lipid turnover and membrane associated signaling events, including Akt signaling (van 
Blitterswijk and Verheij, 2013). Recent studies have also reported that PF increased endogenous 
Cer level to mediate cell apoptosis. In particular, it has been shown that PF enhanced Cer 
production when administered in combination with histone deacetylase inhibitors (HDACi) 
(Rahmani et al., 2005), curcumin (Chen et al., 2012), paclitaxel (Sun et al., 2011), and UVB 
radiation (Ji et al., 2012). However, in some cell lines, PF-induced Cer production is subject to 
metabolic clearance, and is not enough to promote cell death (Yao et al., 2013). In a human 
glioblastoma cell line (U87MG), it has been shown that PF only slightly enhanced Cer production, 
while exogenously added short-chain Cer (C6) inhibited PF-induced protective autophagy to restore 
cell apoptosis and PF sensitivity (Qin et al., 2013). Interestingly, in non-small cell lung cancer cell 
lines PF, through SMase-mediated generation of Cer, stimulated the release of nanovesicles 
containing molecules involved in cell signaling, including active Akt, EGFR (epidermal growth 
factor receptor), and IGF-IR (insulin-like growth factor receptor), decreasing their cellular levels. 
The increase of Cer determined by PF also induced cell detachment and death. Furthermore, when 
transferred in vitro, PF-induced nanovesicles increased Cer levels and death in recipient cells. These 
findings indicate that in these cells Cer generation underlies the Akt inhibition and cytotoxicity of 
PF, and suggest nanovesicles shedding and uptake might potentially propagate their cytotoxicity in 
vivo (Gills and Dennis, 2009). There are also many PF targets in signal transduction pathways, in 
addition to that mentioned above, which might contribute to its mechanism of action. These targets 
may be either primary or secondary targets, probably depending on cellular context (Fensterle et al., 
2014). One of these targets is the Jun N-terminal kinase (JNK). Several pathways, including cellular 
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stress, can activate JNK, which exerts a pro-apoptotic activity e.g. by phosphorylating and thus 
inactivating the antiapoptotic protein Bcl-XL. The activation of JNK has been shown to be 
important for PF-induced apoptosis (Carrasco et al., 2010; Chiarini et al., 2008; Gajate et al., 1998; 
Li et al., 2006; Papa et al., 2008; Ruiter et al., 1999). PF was also shown to reduce the expression of 
survivin and xiap, which are essential pro-survival proteins of the iap family, while increasing at the 
same time the expression of the proapoptotic trail receptor/death-receptor 5 (Fensterle et al., 2014). 
Finally, some authors have shown that PF can have either an inhibitory effect on Erk, a member of 
the Ras/Raf/Mek/Erk cascade (Fei et al., 2010; Papa et al., 2008; Pinton et al., 2012), or leads to its 
activation (Hideshima et al., 2006; Hou et al., 2014; Leleu et al., 2007). These opposing results may 
indicate that modulation of Erk activity plays only a minor role in the anticancer activity of PF as 
compared to other PF-effects constantly observed for a large number of different cell types 
(Fensterle et al., 2014). 
 
 




AIM OF THE WORK 
 
GBM is the most frequent malignant primary brain tumor in adult and one of the most lethal human 
cancers, presenting one of the greatest challenges in oncology. Despite the use of the latest surgical, 
radiation, and chemotherapy treatments, patients with GBM have a poor prognosis, with a median 
survival rate of only 15 months (Rich and Bigner, 2004; Wen and Kesari, 2008). Indeed, GBM 
anatomical location and its complex and heterogeneous biology enormously complicate the use of 
conventional therapies and the development of new treatments (Holland, 2000; Mrugala, 2013). PF 
is a synthetic lipid analogue belonging to a relatively new class of structurally related antitumor 
agents: the APLs. These compounds constitute appealing candidates to develop novel therapeutic 
approaches to treat cancer. Indeed, the mechanisms of action of APLs are different from that of 
standard chemotherapeutic drugs. APLs do not interact directly with the DNA, but rather target the 
cell membranes, where they preferentially accumulate due to their amphiphilic nature (van 
Blitterswijk and Verheij, 2013). Mounting evidence demonstrates that PF exerts a marked cytotoxic 
effect on a wide range of human cancers, both in vitro and in vivo, and is currently being tested in 
phase II clinical trial against major human tumors (Fensterle et al., 2014; Gills and Dennis, 2009). 
However, the effect of PF against gliomas is poorly investigated. Accumulating literature suggests 
that PF could act on tumor cells eliciting apoptosis and/or cell growth arrest. More in detail, it has 
been indicated that the inhibition of the survival signaling pathway PI3K/Akt, which is frequently 
up-regulated in GBM cells, is one of the main mechanism by which PF exerts its antitumor effects 
(van Blitterswijk and Verheij, 2013). However, besides Akt, PF affects other several important 
cellular targets and so the relevance of Akt inhibition for its activity would still be an open question 
(Fensterle et al., 2014; Gills and Dennis, 2009). As other ALPs, PF may disturb cell membranes, 
provoking a broad range of biological effects, ultimately leading to cell death. Indeed, PF may 
induce a biophysical disturbance of cell membrane in which it is inserted, affecting membrane lipid 
turnover and membrane associated signaling events (including Akt signaling) and/or interfere with 
the metabolism and transport of membrane lipids, thus affecting cell membranes composition and 
functionality (Marco et al., 2014). In particular, it has been shown that PF could modify the 
properties of lipid rafts (Fensterle et al., 2014), ordered membrane lipid domains, enriched in 
cholesterol and SLs, serving as sorting platforms and hubs for signal transduction proteins (Sonnino 
and Prinetti, 2013). Numerous signaling pathways involved in cancer development and progression, 
such as cell adhesion, migration, as well as cell survival and growth, are dependent on these 
structures (Mollinedo and Gajate, 2015). It has been well established that SLs exert a key role in the 
formation, stabilization, and function of lipid domains (Sonnino and Prinetti, 2013). Therefore, 
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altered SLs content and/or altered ratio between SLs and glycerophospholipids could influence lipid 
membrane domains formation and behavior.  
On these premises, the aim of this PhD project was to investigate the effect of PF on cell survival in 
different GBM cells, and to provide a contribution to the understanding of its molecular mechanism, 
evaluating the ability of PF to target membrane lipid metabolism and content, that ultimately can 








All reagents were of the highest purity available. DMEM, L-glutamine, streptomycin, penicillin, 
amphotericin-B, sodium pyruvate, aprotinin, leupeptin, pepstatin, bestatin, fatty acid free bovine 
serum albumin (BSA), O-Tricyclo[5.2.1.02,6]dec-9-yl dithiocarbonate potassium salt (D609), 3-
[4,5-dimethylthiazol-2-yl] 2,5-diphenyl tetrazolium bromide (MTT), 2′-(4-Ethoxyphenyl)-5-(4-
methyl-1-piperazinyl)-2,5′-bi-1H-benzimidazole trihydrochloride (Hoechst 33342), 3,6-
bis[dimethylamino]acridine (acridine orange), primary rabbit anti-LC3B antibody, Kodak Biomax 
film and other common chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA). Fetal 








H]Choline, 75 Ci/mmol), 
Ultima Gold were from PerkinElmer Life Sciences (Boston, MA, USA). LY294002 (2-(4-
Morpholinyl)-8-phenyl-4H-1benzopyran-4-one) was from Vinci-Biochem (Firenze, Italy). The 
Primary antibody recognizing phospho-Akt (Ser-473) were from Cell Signaling Technology, Inc. 
(Danvers, MA). Goat anti-mouse horseradish peroxidase-linked secondary antibody was from 
Thermo Fisher Scientific (Waltham, MA, USA). Primary rabbit anti-GAPDH antibody, primary 
rabbit anti-pERK1/2 antibody, primary mouse anti-ERK2 antibody, and Goat anti-rabbit 
horseradish peroxidase-linked secondary antibody were from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). High performance thin layer chromatography (HPTLC) silica gel plates and all 
solvents were from Merck (Darmstadt, Germany). SuperSignal West Pico and West Femto 
Maximum Sensitivity Chemioluminescent Substrate and bovine serum albumin (BSA) fraction V 
were purchased from Pierce Chemical Co (Rockford, IL, USA). 6-((N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl) amino) hexanoyl) sphingosine (NBD-C6-Cer) was from Life Technologies (Italy). D-
threo1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) and DL-threo-1-phenyl-2-
palmitoylamino-3-morpholino-1-propanol (PPMP) were from (Biomol International, Plymouth 
Meeting, PA). Perifosine (D-21266 o octadecyl-(1,1-dimethyl-piperidino-4-yl)-phosphate) was 
from Aeterna Zentaris (Frankfurt am Maim, Germany). PD98059 (2-(2-amino-3-methoxyphenyl)-











4.1 Cell cultures 
 
U87MG, CCF-STTG1 and T98G human glioblastoma multiforme cell lines were obtained from the 
Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia (Brescia, Italy). U87MG cell 
line was cultured in a humidified atmosphere at 37° C with 5% CO2, and maintained in DMEM 
containing: 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, 
100 μg/ml streptomycin and 0.25 μg/ml amphotericin B;  CCF-STTG1 and T98G cell lines were 
cultured in DMEM supplemented with also 1 mM sodium pyruvate. The culture medium was 
usually changed every 48 hours. Cells were maintained by serial passages in 75 cm
2
 culture flasks. 
At reaching confluence, subculture was prepared using a 0.025% trypsin–0.01% EDTA solution. 
Cells were re-suspended in DMEM 10% FCS, counted by trypan blue dye exclusion test using a 




) to allow cell propagation. All cell 
models were plated for experiments at the opportune density in different culture plate dishes (3.5, 6 
or 10 cm of diameter) or in 24-well plates (1.8 cm of diameter). 
 
4.2 Cell treatments 
 
For cell treatments, stock solutions were prepared by dissolving the different molecules as follows: 
- PF: 64.8 mM stock solutions were prepared in absolute ethanol; 
- LY294002: 32.5 mM stock solutions were prepared in DMSO; 
- PD98059: 50 stock solutions were prepared in DMSO; 
- D609: 10 mM were prepared in distilled water; 
- PPMP: 4 mM were prepared in absolute ethanol; 
- PDMP: 10 mM were prepared in absolute ethanol; 
Stock solutions were diluted extemporaneously in fresh medium at the desired concentrations and 
administered to cells for the indicated period of time. Of relevance, ethanol and DMSO final 
concentrations in the culture medium were always maintained below 0.5%, concentrations that do 
not affect cell survival. In each experiment untreated cells were incubated with vehicles at the same 






4.3 Analysis of cell viability: MTT assay 
 
Cell viability was determined by MTT colorimetric assay. U87MG, CCF-STTG1 and T98G cells 
were seeded at 1 x 10
4
, 6.5 x 10
4




respectively in 24 well plates. The day after 
cells were treated with different agents for the indicated periods of time. The medium was then 
replaced by MTT dissolved in fresh medium (0.8 mg/ml) for 4 hours. The formazan crystals formed 
in viable cells were then solubilized in iso-propanol/formic acid (95:5 v/v) for 10 minutes with 
constant stirring to ameliorate the lysis process. The absorbance at 570 nm was measured using a 
microplate reader (Wallack Multilabel Counter, Perkin Elmer, Boston, MA, USA). 
 
4.4 Immunoblotting analyses 
 
Protein expression levels were evaluated using different conditions of cell lysis, SDS-PAGE and 
Western blotting depending on the antigen analysed, as described below. 
In all cases a small aliquot of cell lysates was analyzed for the protein content with the Comassie 
Blue-based assay (Sedmak and Grossberg, 1977). The remaining lysate was denatured by the 
addition of Sample Buffer 4X (containing 0.25 M Tris- HCl pH 6.8, 40% (v/v) glycerol, 8% (w/v) 
SDS, 0.2% (w/v) bromophenol blue, 0.4 M DTT) and by heating for 5 minutes at 100 °C. Then, 




Cells were washed with ice cold PBS for three times and lysed with a lysis buffer containing 20 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 10 mM NaF, 1 mM Na3VO4, 10 mM 
sodium pyrophosphate (Na4P2O7), 1 mM PMSF in the presence of proteases inhibitors (2 µg/ml 
pepstatin, 2 µg/ml aprotinin, and 2 µg/ml leupeptin). After 20 minutes of constant stirring at 4 °C, 
solubilized proteins were centrifuged at 8000 x g for 10 minutes at 4°C.  
Proteins were resolved by SDS-PAGE on 10% of polyacrylamide gel and transferred onto 
nitrocellulose membranes. Membranes were then blocked, under constant stirring, for 1 hour at 
room temperature in Tris-buffered saline (25mM Tris-Cl pH 7.4, 154 mM NaCl), containing 0.1% 
Tween 20 and 5% skim milk. Once blocked, membranes were incubated overnight at 4 °C with a 
primary antibody against phospho-Akt (Ser473) (1:1000) and then with goat anti-mouse IgG (H+L) 




Phosho-ERK and total ERK 
 
Cells were washed with ice cold PBS containing 100 µM Na3VO4 for three times and lysed with a 
lysis buffer containing 20 mM Tris-HCl pH 7.4, 1.5 mM EGTA, 1% Triton X 100, 5 mM Na-β-
glicerophosphate, 2 mM Na3VO4, 2 mM sodium pyrophosphate (Na4P2O7), 1 mM PMSF, 1 mM 
benzamidine, in the presence of proteases inhibitors (2 µg/ml aprotinin, and 2 µg/ml leupeptin). 
After 20 minutes of constant stirring at 4 °C, solubilized proteins were centrifuged at 8000 x g for 
10 minutes at 4 °C. Cell lysates were homogenized using a probe type sonicator. 
Proteins were resolved by SDS-PAGE on 10% of polyacrylamide gel and transferred onto 
nitrocellulose membranes. Membranes were then blocked, under constant stirring, for 1 hour at 
room temperature in Tris-buffered saline (25mM Tris-Cl pH 7.4, 154 mM NaCl), containing 0.1% 
Tween-20 and 5% skim milk. Once blocked, membranes were incubated for 1 h at room 
temperature with a primary antibody against phospho-ERK (pThr/pTyr) (1:500) and then with goat 
anti-rabbit IgG (H+L) peroxidase-conjugated (1:1350) as a secondary antibody for 1 hour at room 
temperature. The membranes were stripped 30 minutes at 50 °C in a buffer containing 2% SDS, 100 
mM DTT, 0.5 M Tris-HCl pH 6.8, washed in TBS-T and blocked, under constant stirring, for 1 
hour in Tris-buffered saline (25mM Tris-Cl pH 7.4, 154 mM NaCl) containing 0.1% Tween-20 
(TBS-T) and 5% skim milk. Once blocked, membranes were incubated for 1 h at room temperature 
with a primary antibody against ERK2 (1:500) and then with goat anti-mouse IgG (H+L) 




Cells were washed with ice cold PBS for three times and lysed with a lysis buffer containing 20 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 10 mM NaF, 1 mM Na3VO4, 10 mM 
sodium pyrophosphate (Na4P2O7), 1 mM EDTA, 1 mM PMSF in the presence of proteases 
inhibitors (2 µg/ml pepstatin, 2 µg/ml aprotinin, and 2 µg/ml leupeptin). After 20 minutes of 
constant stirring at 4 °C, solubilized proteins were centrifuged at 8000 x g for 10 minutes at 4 °C.  
Proteins were resolved by SDS-PAGE on 18% of polyacrylamide gel and transferred onto 
nitrocellulose membranes. Membranes were then blocked, under constant stirring, for 1 hour at 
room temperature in Tris-buffered saline (25mM Tris-Cl pH 7.4, 154 mM NaCl), containing 0.05% 
Tween-20 and 5% skim milk. Once blocked, membranes were incubated for 1 h at room 
temperature with a primary antibody against LC3B (1:1000) and then with goat anti-rabbit IgG 




In all cases, immunoblots were probed with an antibody for GAPDH as a protein loading control. 
Bound antibodies were visualized by the enhanced chemiluminescence method using SuperSignal 
West Pico Maximum sensitivity Chemioluminescent Substrate, and membranes were exposed to 
Kodak Biomax films. The relative abundance of each protein band was analysed via densitometry 
scanning of the exposed films.  
 
4.5 Fluorescence studies: cell apoptosis analysis with Höechst staining and acidic vesicular 
organelles detection with acridine orange staining 
 













 respectively on a glass coverslip. After 48 hours, cells were incubated with PF at the 
indicated concentrations in culture medium. After 48 hours or 72 hours of treatment, cells were 
incubated in the dark at 37 °C with 1 µg/mL acridine orange (Sigma-Aldrich, St Louis, MO) for 20 
min and with 5 µM Höechst 33342 (Sigma-Aldrich, St Louis, MO) in the last 15 min. Cells were 
then washed three times in PBS for 5 minutes with constant stirring, fixed with 0.5% glutaraldehyde 
solution in PBS for 10 minutes at 4°C, and analyzed with a fluorescence microscope (Olympus BX-
50) equipped with a fast high-resolution CCD camera (Colorview 12) and an image analytical 
software (Soft Imaging System GmbH, Olympus, Munster, Germany). 
 
4.6 Metabolic studies 
 








. After 48 
hours, cells were incubated in fresh culture medium in the presence or absence of 10 µM PF for 4 
hours. In the last 30 minutes or in the last 120 minutes of treatment, cells were pulsed with 0.5 
µCi/dish radiolabeled sphingosine ([C3-
3
H]Sphingosine, 21.4 Ci/mmole) in the conditioned 
medium. Cells were then collected and submitted to lipid extraction, partitioning, and methanolysis, 







Pulse experiments with [methyl-3H]Choline 
 




. After 48 
hours, medium was gently removed and cells were then fed with 1.92 µCi/dish radiolabeled choline 
([methyl-3H]Choline, 75 Ci/mmole), in fresh culture medium in presence or absence of 10 µM PF 
for 4 hours. Cells were then collected and submitted to lipid extraction and partitioning, as 
described below. 
 
Extraction and partitioning of intracellular lipids 
 
At the end of pulse, cells were washed three times in ice-cold PBS and harvested with an 
appropriate volume of methanol. Then, an appropriate volume of chloroform was added in order to 
obtain the final chloroform/methanol ratio 2:1 (v/v). After mixing for 15 minutes, samples were 
centrifuged at 10000 x g for 15 minutes at 4 °C. The supernatant was collected and the pellet was 
re-extracted  by adding 500 µl chloroform/methanol 2:1 (v/v), mixed and centrifuged. The second 
supernatant obtained was added to the first one. The two supernatants combined represent the total 
lipid extract (TLE). An aliquot of the TLE was counted for radioactivity by liquid scintillation. 
Pellets obtained after lipid extraction, containing cellular proteins, were dried a under nitrogen 
stream and digested over night with 50 µl 1N NaOH at R.T. Digestion was stopped with 450 µl 
distilled water. Aliquots were analyzed for protein content with the Lowry based assay (Lowry et 
al., 1951). An aliquot of 1.5 ml of TLE was partitioned by adding 375 µl of distilled water. After 
vigorous and repeated shaking, phases were separated by centrifugation at 8500 x g for 5 minutes at 
4°C. At the end of the centrifugation a biphasic solution was obtained, composed of an upper 
aqueous phase, containing the more polar intracellular lipids (S1P and gangliosides) and a lower 
organic phase, containing the more apolar intracellular lipids (Cer, GlcCer , LacCer, Sph, SM and 
glycerophospholipids). Aqueous phase was transferred to new glass tube, while organic phase was 
washed with a volume of chloroform/methanol /water 3:48:47 (v:v:v) corresponding to that of the 
aqueous phase collected, mixed and centrifuged. The second aqueous phase obtained was added to 
the first one. Organic phase was evaporated under a nitrogen stream, dissolved in 
chloroform/methanol 2:1 (v/v) counted for radioactivity by liquid scintillation and then analysed by 
HPTLC (as described below). Alternatively, organic phase was submitted to mild alkaline 





Mild alkaline methanolysis of the organic phase 
 
The organic phase was evaporated to dryness under a nitrogen stream and then re-dissolved in 50 µl 
chloroform.  After the addition of 50 µl of 0.2 N KOH in methanol, the samples were mixed and 
incubated 1 hour at 37 °C under constant stirring. The reaction was stopped by neutralization with 
60 µl of 0.2 N HCl in methanol. Then, 90 µl methanol and 350 µl chloroform were added in order 
to reach the final chloroform/methanol ratio 2:1 (v/v). After mixing, phases were separated by the 
addition of 95 µl water and centrifugation at 8500 x g for 5 minutes at 4 °C. The upper aqueous 
phase was removed and the lower organic phase was dried under a nitrogen stream, re-suspended 
with 300 µl chloroform/methanol 2:1 (v/v), counted for radioactivity by liquid scintillation and 
analysed by HPTLC (as described below). 
 
Separation and quantification of radiolabeled sphingolipids by HPTLC 
 
The radiolabeled sphingolipids recovered in the organic phase or in the methanolysed organic phase 
were submitted to high performance thin layer chromatography (HPTLC) on silica gel plates, 
developed in a chromatographic chamber by the use of appropriate solvent systems as follows. 
Sphingolipids contained in the methanolysed organic phase from cells pulsed with [C3-
3
H]Sphingosine were separated using chloroform/methanol/water 110:40:6 (v/v/v) as solvent 
system. A standard mix composed of tritiated Cer, GlcCer, LacCer, Sph, and SM was 
chromatographed on the same plate and used as internal standard. 
Phospholipids contained in the organic phase from cells pulsed with [methyl-
3
H]Choline were 
separated using chloroform/methanol/acetic acid/water 50:30:8:5 (v/v/v/v) as solvent system. 
Radiolabeled SM and PC were chromatographed on the same plate and used as internal standard. 
HPTLC plates were then dried and submitted to digital autoradiography (Beta-Imager 2000, 
Biospace, Paris, FR). The radioactivity associated with individual lipids was quantified by the beta 
vision analysis software (Biospace, Paris, FR). 
 
4.7 Sphingomyelin synthase and glucosylceramide synthase activity assays 
 
Sphingomyelin synthase and glucosylceramide synthase activity assay in cell culture 
 




. After 48 
hours, cells were incubated with or without 10 µM PF for 3 hours and 30 minutes in culture 
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medium. At the end of the treatments, the medium was collected and the cells were loaded with 5 
µM NBD-C6-Cer (as 1:1 complex with fatty acid free BSA) in KRH solution, containing 25 mM 
HEPES-NaOH pH 7.4, 125 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 6 mM 
glucose and 2 mM CaCl2, at 4 °C for 30 minutes. After loading, the cells were washed twice in PBS 
containing fatty acid free BSA (0.34 mg/ml) and then incubated for 30 minutes at 37 °C in the 
appropriate conditioned medium. At the end of the incubation, cells were immediately put at 4 °C to 
stop the enzymatic reaction; then, cell lipids were extracted with chloroform/methanol as described 
above in order to obtain the TLE. A small aliquot of TLE from each sample was analyzed for 
fluorescence-labeled lipids content with a luminescence spectrometer (LS50B PerkinElmer). Lipids 
were separated by high performance thin-layer chromatography (HPTLC) using 
chloroform/methanol/15 mM CaCl2 60:35:8 (vol/vol/vol) as solvent system. The bands 
corresponding to the reaction products NBD-C6-SM and NBD-C6-GlcCer and to the substrate 
NBD-C6-Cer of each sample, were separately scraped off the HPTLC plates and lipids were 
extracted from the silica gel with 500 µl chloroform/methanol/0.1 M KCl 1:2:0.8 (vol/vol/vol). 
After mixing, samples were centrifuged at 10000 x g for 15 minutes at 4 °C. The supernatant was 
collected and the precipitated was re-extracted with 500 µl chloroform/methanol/0.1 M KCl 1:2:0.8 
(vol/vol/vol), mixed and centrifuged. The second supernatant obtained was added to the first one.  
Fluorescence-labeled SM, GlcCer and Cer were quantified with a luminescence spectrometer 
(LS50B PerkinElmer). 
 
Cell-free sphingomyelin synthase and glucosylceramide synthase activity assay 
 




. After 48 
hours, cells were washed three times with ice-cold PBS, harvested and homogenized using a probe 
type sonicator. Protein concentration of cell homogenates was determined by the Lowry method 
(Lowry et al., 1951). SMS and GCS activities were assayed using experimental conditions known to 
selectively favor SMS or GCS activity. 
For the SMS activity assay, a reaction mixtures consisting of 50 mM Tris-HCl pH 7.4, 25 mM KCl, 
0.5 mM EDTA, and 40 µM NBD-C6-Ceramide (as 1:1 complex with fatty acid free BSA) 
supplemented with or without 10 µM PF was prepared and added to 12.5 γ or 25 γ of cell 
homogenate in a final volume of 50 µl. 
For the GCS activity assay, a reaction mixtures consisting of 50 mM Tris-HCl pH 7.4, 25 mM KCl, 
5 mM UDP-glucose, 10 mM MnCl2, and 40 µM NBD-C6-Ceramide (as 1:1 complex with fatty acid 
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free BSA) supplemented with or without 10 µM PF was prepared and added to 12.5 γ or 25 γ of cell 
homogenate in a final volume of 50 µl. 
After an incubation period of 15 minutes at 37 °C in the dark and in constant stirring, the reaction 
was stopped by adding 150 µl chloroform/methanol 1:2 (v/v). 
After mixing, samples were centrifuged at 10000 x g for 10 minutes at 4 °C. After being transferred 
to new glass tube, 150 µl chloroform was added to the supernatant and then the samples were mixed 
and centrifuged at 8500 x g for 10 minutes at 4 °C. At the end of the centrifugation a biphasic 
solution was obtained, composed of an upper aqueous phase and a lower organic phase, containing 
the reaction products NBD-C6-SM and NBD-C6-GlcCer and the remaining substrate NBD-C6-Cer.  
The organic phase was transferred to a new glass tube, dried under nitrogen stream and resuspended 
in chloroform/methanol 2:1 (v/v). Fluorescence-labeled SM, GlcCer, and Cer were then resolved on 
HPTLC, scraped off the HPTLC plates, extracted from the silica gel, and quantified with a 
luminescence spectrometer (LS50B PerkinElmer) as describe above. 
 
4.8 Analysis of the endogenous phospholipids and gangliosides 
 




. After 48 
hours, cells were incubated with or without 10 µM PF in fresh culture medium supplemented with 
0.5% FCS for 48 hours. At the end of treatments, cell lipids were extracted with 
chloroform/methanol (as described above) in order to obtain the TLE and then partitioned (as 
described above). An aliquot of the organic phase containing phospholipids as lipid molecules of 
interest was used to determine the phospholipid content, according to the Bartlett assay, a 
colorimetric assay based on the determination of liberated inorganic phosphate (Bartlett, 1959). 
Phospholipids were submitted to HPTLC using chloroform/methanol/acetic acid/water 50:30:8:5 
(v/v/v/v) as a solvent system. The HPTLC plate was then sprayed with the Vaskovsky V.E. and 
Kostetsky E.Y. reagent (Vaskovsky and Kostetsky, 1968) and incubated at 120 °C for 15 minutes. 
The relative abundance of each spot was quantified by densitometric scanning of the HPTLC plate. 
The acqueous phase containing gangliosides as lipid molecules of interest was dried under a 
nitrogen stream, and resuspended in chloroform/methanol 2:1 (v/v). Gangliosides were then 
submitted to HPTLC using chloroform/methanol/15 mM CaCl2 55:45:10 (vol/vol/vol) as a solvent 
system. The HPTLC plate was then sprayed with the Ehrlich reagent and incubated at 120 °C for 15 





4.9 Protein assays 
 
Protein content was evaluated using the Bradford/Comassie blue-based assay (Sedmak and 
Grossberg, 1977) or the Lowry assay (Lowry et al., 1951). In both cases bovine serum albumin 
fraction V was used as standard. The protein content was obtained by spectrophotometric reading at 
595 nm for the Bradford assay and 750 nm for the Lowry assay. 
 
4.10 Statistical analysis 
 
Results are expressed as mean value ± SD for at least three independent experiments. The statistical 
significance of differences was determined by the Student’s t test. A p value < 0.05 was considered 





5.1 Effect of Perifosine on GBM cells viability 
 
Evidence in literature indicates that the cytotoxic effects of PF can differ depending on cell types 
(van Blitterswijk and Verheij, 2008). Up to now, only few studies have investigated the efficacy of 
PF against gliomas (Becher et al., 2010; de la Pena et al., 2006; Momota et al., 2005; Pitter et al., 
2011; Qin et al., 2013; Rios-Marco et al., 2013; Rios-Marco et al., 2015) and much remains to be 
clarified about its mechanisms of action. So, we first evaluated the effect of PF on cell survival in 
three human GBM cell lines: T98G, CCF-STTG1 and U87MG, which are characterized by a 
different mutation status of PTEN. In particular, T98G cells are wild type for PTEN, while CCF-
STTG1 and U87MG cells are mutant for PTEN (Zhang et al., 2007b); ours unpublished data) and 
therefore have constitutively activated Akt. For this purpose, the three cell lines were treated with 
PF at concentrations ranging from 5 µM to 60 µM in complete medium. After 48 hours we 
performed MTT assay to evaluate cell viability. The results obtained demonstrated that PF reduced 
cell viability in a dose-dependent manner in all GBM cell lines tested (Fig. 6). Moreover, our 
experiments show that this cytotoxic effects increased with increasing exposure time (data not 
shown). The drug sensitivity parameter ED50 (dose required to reduce cell viability by 50%) was 
calculated after 48 hours of treatment with PF. The T98G, CCF-STTG1, and U87MG cell lines 
showed an ED50 value of 12.9 ± 0.65 µM, 37.3 ± 1.86 µM, and  19.3 ± 0.96 µM, respectively. 
These results suggest that in these cell lines the sensitivity to PF did not correlate directly with basal 







Figure 6. PF cytotoxicity in different GBM cell lines. Cells were left untreated or exposed to different doses of PF. Cells 
viability was assessed after 48 h of treatment by MTT assay. The results are expressed as a percentage of viable cells 
with respect to control untreated cells and presented as means ± SD of three independent experiments. Asterisks 
represent statistical significance determined by Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001 vs untreated cells). 
 
5.2 Effect of Perifosine on Akt activation in GBM cells 
 
Subsequently, we investigated the effect of PF on Akt phosphorylation. We treated the three GBM 
cell lines with concentrations of PF giving a 25-40% decrease of cell viability in complete medium 
supplemented with fetal bovine serum as growth stimulus. Moreover, cells were treated with 
LY294002 (LY29), a known PI3K/Akt inhibitor (Knight, 2010), as positive control. At the 
indicated times, cells were lysed and the same amount of proteins for each sample was resolved in 
SDS-PAGE. Our immunoblotting analyses (reported in Fig. 7, panel A and B) indicated that PF 
promoted a decrease of p-Akt(Ser473) levels in a time-dependent manner, with a similar trend in all 
GBM cell lines analyzed. We found that PF reduced the p-Akt levels in T98G and CCF-STTG1 
cells by 50% and 60% respectively after 3 hours of treatment, reaching an almost total inhibition of 
Akt after 24 hours of treatment (Fig. 7, panel A). In U87MG cells 10 µM PF induced a decrease of 
p-Akt levels of 30% and 70% after 4 and 24 hours of treatment respectively, while 20 µM PF 
induced a decrease of p-Akt levels of about 30% and 70% after only 2 and 4 hours of treatment 
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respectively, and induced an almost complete inhibition of Akt already after 8 hours of treatment 
(Fig. 7, panel B). On the other hand, in the same GBM cell lines, p-Akt was undetectable after just 1 




Figure 7. Effect of PF on Akt phosphorylation in different GBM cells. Cells were treated in the presence or absence of 
PF at the indicated concentrations and for the indicated times or in the presence or absence of 10 µM LY29 for 1 h. 
Cells were then harvested in lysis buffer for immunoblotting analysis of p-Akt and GAPDH levels, as described in 
“Material and Methods” section. Equal amounts of protein from each sample were analyzed by immunoblotting with an 
anti-p-Akt antibody and an anti-GAPDH antibody. The levels of p-Akt was determined by densitometric quantitation 
and normalized for GAPDH levels. Values are mean ± SD of three independent experiments. Asterisks represent 
significant differences between control and treated cells (*p <0.5; **p < 0.01, Student’s t test). 
 
5.3 Effect of Perifosine in combination with LY294002 on U87MG cells viability 
 
As previously mentioned, the inhibition of Akt activation/phosphorylation is considered one of the 
main mechanism by which PF causes its cytotoxic effect (Gills and Dennis, 2009; Hennessy et al., 
2007; Kondapaka et al., 2003; van Blitterswijk and Verheij, 2013). However, recently it has been 
reported that PF could determine also Akt-independent effects (Fensterle et al., 2014), resulting in 
cell demise. So, we wonder if PF is still able to induce cytotoxic effects even in a condition in 
which Akt is completely inhibited, such as treating cells with the LY29 compound. Therefore, 
U87MG cells were treated with PF in presence or absence of LY29. After 48-72 hours cell viability 
was evaluated by MTT assay. As shown in Fig. 8, both PF and LY29 alone were able to decrease 
cell viability. Moreover, the co-treatment of PF and 5 µM LY29 induced an about 24% and 30% 
decrease of cell viability at 48 and 72 hours respectively, compared to cells treated only with 5 µM 
LY29. Similar results were obtained using 10 µM LY29. This result thus suggested that PF exerts 






Figure 8. Effect of PF in combination with LY29 on U87MG cells viability. Cells were cultured in control media or 
exposed to 10 µM PF, 10 μM LY29, separately or in combination, as indicated. Cells viability was assessed after 48 h 
and 72 h of treatment by MTT assay. The results are expressed as a percentage of viable cells with respect to control 
untreated cells and presented as means ± SD of three independent experiments. Asterisks represent statistical 
significance determined by Student’s t test (*p < 0.05; **p < 0.01 vs PF-treated cells; #p<0.05; ##p<0.01 vs LY29-
treated cells). 
 
5.4 Effect of Perifosine on [methyl-
3
H]Choline metabolism in U87MG cells 
 
Increasing evidence suggests that in different cell lines PF, such as other ALPs, is able to inhibit the 
rate-limiting enzyme CT and, consequently, the biosynthesis of PC (Marco et al., 2009; Tafesse et 
al., 2006; van Blitterswijk and Verheij, 2013; Wieder et al., 1998). In some cases, the inhibition of 
PC biosynthesis is considered a crucial event to lead to cell death, through still unclear mechanisms. 
PC is the donor of phosphocholine in the reaction catalyzed by the enzyme SMS (Diringer et al., 
1972; Riboni et al., 1997). So, in accordance with the precursor-product relationship, the inhibition 
of the PC biosynthesis may also affect the SM biosynthesis from PC and Cer and, as a consequence, 
may induce the accumulation of this last pro-death lipid. 
Based on these assumptions, we perform a pulse experiment with radiolabeled choline. Cells were 
fed with [methyl-
3
H]Choline for 4 hours in the absence or presence of PF. We found that the uptake 
of radiolabeled choline was similar in treated and untreated cells (data not shown). On the other 
hand, PF treatment significantly reduced the incorporation of [methyl-
3
H]Choline into PC and SM 





H]SM ratio with respect to untreated cells, suggesting that even if the PC 








H]Choline metabolism in 87MG cells treated with PF. Cells were pulsed with 1.6 µCi/dish [methyl-
3
H]Choline for 4 h in the absence or presence of 10 µM PF. At the end of pulse, cells were harvested and submitted to 
lipid extraction and partitioning. The organic phase was analysed by HPTLC and submitted to digital autoradiography. 
Experiments were done in triplicate, data are mean  SD. Asterisks represent significant differences between control 
and treated cells (*p < 0.5; **p < 0.01, Student’s t test). 
 
5.5 Effect of Perifosine on [C3-
3
H]Sphingosine metabolism in U87MG cells 
 
Since we demonstrated that PF affected SM biosynthesis in U87MG cells, we investigated the 
effect of PF on Cer metabolism. To this purpose, we performed short time pulse experiments (30 
and 120 minutes), in the absence or presence of PF, by feeding cells with [C3-
3
H]Sphingosine. 
Cells were able to efficiently and rapidly internalize this radiolabelled SL, as Cer precursor. The 
incorporated radioactivity, present in the total lipid extract, increased in a time-dependent manner 
and was similar in untreated and treated cells (data not shown), indicating that treatment with PF 
did not alter the [C3-
3
H]Sphingosine uptake. Moreover, at both 30 and 120 minutes of pulse, [C3-
3
H]Sphingosine represented only a minor part of incorporated radioactivity in control and PF-
treated cells (Fig. 10), suggesting that cells rapidly metabolized Sph in all considered experimental 
conditions tested (Fig. 10). More in detail, at short pulse times, most of the incorporated [C3-
3
H]Sphingosine was metabolized to N-acylated compounds (constituted for the most part of Cer, 
and in a lesser extent, SM and GSLs). The total amount of N-acylation increased with pulse time 
and was very similar in control and PF-treated cells. Furthermore, cells were characterized by a 







H]LacCer. Of relevance, PF-treatment was able to significantly modify the distribution of the 
radioactivity associated to the different Sph N-acylated metabolites. In fact, [
3
H]Cer level increased 
in a time-dependent manner after PF treatment, accounting for an increase of 10.6 ± 2.4 % and 32 ± 
5.9 % at 30 minutes and 120 minutes pulse, respectively, in comparison with control cells. In 
parallel, the radioactivity associated to SM was reduced by 37 ± 8.4 % and 41 ± 2.6 % at 30 and 
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120 minutes pulse, respectively (Fig. 10). Furthermore, the radioactivity associated to GSLs 
(GlcCer + LacCer) were reduced by 16 ± 4.3 % and 16 ± 4.8 % at 30 and 120 minutes pulse, 
respectively in treated cells compared to control. 
Therefore, our data indicate that in U87MG cells PF treatment increased Cer levels mostly as a 
result of diminished SM synthesis and, apparently, also as a result of diminished GSLs synthesis, 
without altering the process of Cer synthesis, evaluated from the N-acylation capacity of control 








H]Sphingosine metabolism in U87MG cells treated with PF. Cells were incubated in complete medium 
in the presence or absence of 10 µM PF for 4 h. In the last 30 min (A) or in the last 120 min (B) of treatment, cells were 
pulsed with 0.5 µCi/dish [C3-
3
H]Sphingosine in the conditioned medium. At the end of pulse, cells were harvested and 
submitted to lipid extraction and partitioning. The methanolized organic phase was analyzed by HPTLC and submitted 
to digital autoradiography. Radioactivity associated to the process of Sph N-acylation and intracellular unmetabolized 
[C3-
3
H]Sphingosine is shown. Data are expressed as % of incorporated radioactivity. Values are the means ± SD of 
three independent experiments. Asterisks represent significant differences between control and treated cells (*p < 0.5; 





5.6 Effects of Perifosine on sphingomyelin synthase and glucosylceramide synthase activity in 
U87MG cells 
 
To better investigate the effects of PF treatment on Cer utilization by U87MG cells, we evaluated if 
PF is able to affect SMS and GCS activity. 
To this purpose, we performed a SMS and GCS activity assay both in cell culture and cell-free, 
using a fluorescently labeled Cer derivative, NBD-C6-Cer, as an efficient substrate for both SMS 
and GCS. In the enzymatic activity assay in cell culture, cells treated with or without PF were 
incubated with NBD-C6-Cer. NBD-C6-Cer has a high cellular permeability and, once internalized 
by cells, rapidly targets the Golgi, where it is utilized for the synthesis of NBD-C6-SM and NBD-
C6-GlcCer (Chazotte, 2012). The results obtained show (Fig. 11, panel A) that the NBD-C6-SM 
levels were reduced by about 23% in PF treated cells with respect to control, while the NBD-C6-
GlcCer levels were very similar in treated and untreated cells. In parallel, NBD-C6-Cer levels were 
about 16% higher in PF treated cells than in the control. In the cell-free enzymatic activity assay, 
cellular homogenates were incubated with NBD-C6-Cer in the presence or absence of PF with the 
aim to evaluate if PF was able to directly interacts with SMS and/or GCS activity. The cell-free 
enzymatic activity assay demonstrated that the activity of SMS and GCS was 27 ± 1.5 and 146 ± 24 
nmol/mg protein/min, respectively in untreated control cells. In presence of PF any significant 
variation was observed with respect to untreated cells (Fig. 11, panel B). Taken together, these 
results indicate that PF affects SMS activity, but not GCS activity in U87MG cells and that this 




Figure 11. Effect of PF on SMS and GCS activity in U87MG cells. (A) SMS and GCS activity assay in cell culture. (B) 
Cell-free SMS and GCS activity assay. Experiments were done in triplicate, data are mean  SD. Asterisks represent 







5.7 Effects of Perifosine on endogenous level of Phospholipids in U87MG cells 
 
Since we demonstrated that in U87MG cells PF is able to affect PC and SM biosynthesis, we 
evaluated if PF could affect also the total amount of endogenous PC and SM and if it changes cell 
phospholipids (PLs) profile. We found (Fig.12) that the total PLs/protein ratio was reduced by 
about 26% in treated cells with respect to control (from 488 ± 3.1 nmol PLs/mg protein to 362 ± 
20.6 nmol PLs/mg protein) and that treated cell exhibited a different PLs pattern. Indeed, cells 





Figure 12. Effect of PF on endogenous levels of Phospholipids in U87MG cells. Cells were treated in the absence or 
presence of 7 µM PF in complete medium supplemented with 0.5% FCS for 48 h and then harvested and submitted to 
lipid extraction and partitioning as described in “Material and Methods” section. The organic phase was analyzed by 
HPTLC and PLs were visualized with the Vaskovsky V.E. and Kostetsky E.Y. reagent. Experiments were done in 
triplicate, data are mean  SD. Asterisks represent significant differences between control and treated cells (*p < 0.5; 
**p < 0.01, Student’s t test). 
 
5.8 Effects of Perifosine on endogenous level of Gangliosides in U87MG cells 
 
Since PF slightly but significantly decrease GlcCer and LacCer levels, as we demonstrated in 
metabolic studies performed with [C3-
3
H]Sphingosine, without affect GCS activity, as we 
determined in in vitro and in silico enzymatic assays, we investigate if the reduction in the amount 
of GlcCer and LacCer observed could be due to their rapid utilization for the synthesis of more 
complex GSLs, such as gangliosides. To asses this hypothesis, we analyze if PF is able to alter the 
endogenous levels of gangliosides in U87MG cells. As shown in Fig. 13, PF was able to induce a 






Figure 13. Effect of PF on endogenous level of gangliosides in U87MG cells. Cells were treated in absence or presence 
of 7 µM PF in complete medium supplemented with 0.5% FCS for 48 hours and then harvested and submitted to lipid 
extraction and partitioning as described in “Material and Methods” section. Gangliosides present in the aqueous phase 
were analyzed by HPTLC and then visualized with the Ehrlich reagent. Experiments were done in triplicate, data are 
mean  SD. Asterisks represent significant differences between control and treated cells (*p < 0.5;**p < 0.01, Student’s 
t test). 
 
5.9 Analysis of the mechanism of Perifosine-induced cells death 
 
It has been reported that PF can induce both apoptosis and/or autophagy, depending on cell type 
(Fensterle et al., 2014; Fu et al., 2009; Qin et al., 2013; van Blitterswijk and Verheij, 2013). To 
assess whether PF-exposed GBM cell lines undergo apoptosis and/or autophagy, we performed both 
Höechst 33342 and acridine orange (AO) cell staining after 48 hours of treatment with PF at 
concentration giving 25-40% decrease of cell viability. The first type of staining allows highlighting 
a mechanism of cell death by apoptosis, while the second one allows detecting the presence of 
autophagic cells. As shown in Fig. 14, in all the three GBM cell lines analyzed, Höechst 33342 
staining showed neither condensed chromatin, nor any fragmented nuclei in PF-treated cells, thus 
indicating the absence of apoptosis; on the other hand, AO staining showed the formation of a 
discrete number of cytoplasmatic spots emitting red-orange fluorescence, representative of acidic 
vesicular organelles, that are absent in non-treated cells, suggesting that PF induced autophagy. 
Even after 72 hours of PF-treatment, signs of apoptosis were undetectable in U87MG cells, while 








Figure 14. Mechanism of PF-induced cell death. GBMs cells grown on a glass coverslip were treated in absence or 
presence of (A and C) 10 µM, (B) 30 µM PF for 48 h and 72 h (C). Vital staining was performed labeling cells with 5 
µM Höechst 33342 for 15 min and with 2 µM acridine orange for 20 min. Cells were then fixed and processed for 
immunofluorescence microscopy. The fluorescent microscopy images (magnification, 100X) were processed and 
printed identically. 
 
It has been reported that the AO stain is not a selective marker of only autolysosomes, but can also 
accumulate in other intracellular acidic compartments (Robbins and Marcus, 1963). Different 
specific markers to monitor autophagy have been identified. Autophagosomes formation involves 
the localization of the protein LC3 (Microtubule-assocociated light chain protein 3) in 
autophagosomes, and, between the different homologs, LC3B is most commonly used for 
autophagy assays. In particular, it has been shown that two different isoforms of LC3B exist: 





preautophagosomal and autophagosomal membrane-bound form of LC3B. LC3B-II is characterized 
by the addition of phosphatidylethanolamine (PE) which it is essential for membrane binding. This 
addition induces changes in LC3B-II electrophoretic mobility during SDS-PAGE, LC3B-II 
migrating faster than LC3B-I while having a greater molecular weight. Hence, the amount of 
LC3B-II is closely correlated with the number of autophagosomes and it is considered as an 
excellent marker for autophagosomes detection (Mizushima and Yoshimori, 2007). 
So, the presence of autophagy in U87MG cells exposed to PF was also evaluated analyzing by 
immunoblotting the LC3B conversion from LC3B-I to LC3B-II. 
As shown in Fig. 15, in U87MG cells PF significantly increased the amount of LC3B-II protein in a 




Figure 15. Effect of PF on LC3B-II amount in U87MG cells. Cells were treated with or without 10 µM PF for 48 and 
72 h and then harvested in lysis buffer for immunoblotting analysis of LC3B-I, LC3B-II, and GAPDH levels, as 
described in “Material and Methods” section. Equal amounts of protein from each sample were analyzed by 
immunoblotting with an anti-LC3B antibody, and an anti-GAPDH antibody. 
 
Accordingly, U87MG cells phase contrast images (Fig. 16) show that PF induced the formation of a 
high number of vacuoles within the cytoplasm, maybe representative of autophagosomes, and dense 
bodies scattered throughout the cytoplasm, that could be lysosomes. Notably, as can be appreciated 
both by AO staining and by phase contrast images (Figs. 14 and 16), most of the U87MG cells 
exposed to PF showed an irregular shape, being giant and multinucleated, morphologic changes 
typical of mitotic catastrophe. In particular, multinucleated cells represented about 35% and 73% of 
total PF-treated cells at 48 and 72 hours of treatment, respectively, while they only account for 4% 
of total untreated cells at both time considered (Fig. 17). 
These findings suggest that in GBM cells mitotic catastrophe could be the mechanism of cell death 






Figure 16. Effect of PF on U87MG cells morphology. Representative images of U87MG cells morphology after 48 (A) 
and 72 h (B) of treatment with or without 10 µM PF. Images were viewed on a contrast phase microscope and digital 





Figure 17.  PF induces multinucleation of U87MG cells. The pie chart shows the percentage of cells with 1, 2, 4 or 
more than 4 nuclei on total cells of cells treated in absence or presence of 10 µM PF for 48 and 72 h. 
 
5.10 Effect of Perifosine on ERK activation 
 
It is known that the Akt/mTOR/p70S6K pathway is the main regulatory pathway that negatively 
controls autophagy, while the ERK1/2 pathway regulates autophagy positively (Sridharan et al., 
2011). Several drugs induce autophagy by inhibiting Akt and, at the same time, activating ERK1/2 
(Aoki et al., 2007; Ellington et al., 2006). Since we demonstrated that PF induced autophagy in 
U87MG cells and, from literature, could inhibit or activate ERK1/2, depending on cell type (Fei et 
al., 2010; Hideshima et al., 2006; Leleu et al., 2007; Momota et al., 2005; Papa et al., 2008), we 
analyzed whether PF altered the phosphorylation status of ERK1/2 in U87MG cells through 
immunoblotting experiments. Our data demonstrated that in our cell model, PF maintains ERK in 
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its active/phosphorylated state even up to 24 hours of treatment, without altering the total amount of 




Figure 18. Effect of PF on ERK activation in U87MG cells. Cells were treated with or without 10 µM PF for 2, 4, 8, 
and 24 h and then harvested in lysis buffer for immunoblotting analysis of p-ERK, ERK2, and GAPDH levels, as 
described in “Material and Methods” section. The levels of p-ERK, ERK2, GAPDH were determined by densitometric 
quantitation and normalized for GAPDH. Values are mean ± SD of three independent experiments. Asterisks represent 
significant differences between control and treated cells (*p < 0.5; **p < 0.01, Student’s t test). 
 
5.11 Role of ERK1/2 activity in Perifosine-induced autophagy 
 
To determine whether the activity of ERK is involved in PF-induced autophagy, we used a chemical 
inhibitor of MEK, PD98059 (PD98). As shown in Fig. 19, panel A, pretreatment of U87MG cells 
with PD98 followed by PF incubation for 4 hours led to a drastic inhibition of ERK1/2 
phosphorylation compared with PF-treated cells. Moreover, cells were pretreated or not with PD98 
and incubated with PF for 48 hours. Immunoblotting analysis of LC3B conversion from LC3B-I to 
LC3B-II showed that the pretreatment with PD98 was able to counteract the effect of PF on LC3B-
II formation. Indeed, cells treated with PF in combination with PD98 had a significant decreased in 
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LC3B-II levels than those treated with PF alone (Fig. 19, panel B). These findings demonstrated 




Figure 19. (A) Effect of PD98 on ERK activity in U87MG cells treated with PF. Cells were cultured with control media 
or pretreated in the absence or presence of 10 μM PD98 1 h prior to treatment with 10 µM PF or 10 μM PD98 for 4 h, 
as indicated. At the end of treatments, cells were harvested in lysis buffer for immunoblotting analysis, as described in 
“Material and Methods” section. Equal amounts of protein from each sample were analyzed by immunoblotting with an 
anti-p-ERK antibody and an anti-GAPDH antibody. (B) Effect of PD98 on LC3B-II amount in U87MG cells treated 
with PF. Cells were cultured with control media or pretreated in the absence or presence of 10 μM PD98 1 h prior to 
treatment with 10 µM PF or 10 μM PD98 for 48 h, as indicated. At the end of treatments, cells were harvested in lysis 
buffer for immunoblotting analysis, as described in “Material and Methods” section. Equal amounts of protein from 
each sample were analyzed by immunoblotting with an anti-LC3B antibody, and an anti-GAPDH antibody. 
 
5.12 Effect of Perifosine in combination with PD98059 on U87MG cells viability 
 
The results obtained by immunoblotting experiments showed that in U87MG cells PF is able to 
maintain ERK1/2 in a phosphorylated/active state and that the autophagy induced by PF is also due 
to ERK1/2 activity. In order to understand the role of ERK1/2 activity in PF-induced cytotoxicity, 
we evaluated the effect of PF on U87MG cells viability in the absence or presence of PD98 for 48 
and 72 hours. As shown in Fig. 20, treatment with PF alone induced a decrease in cell survival of 
about 25% at 48 hours, in comparison with control cells, while PD98 treatment by itself induced a 
decrease of cell viability of about 56% at 48 hours, with respect to control. Intriguingly, treatment 
with PF combined with PD98 further decreased cell survival of about 55% compared to PF alone 
and of about 22% with respect to cells treated only with PD98. Similar results were obtained at 72 
hours of treatment. These findings suggest that ERK1/2 activity protects cells from PF-induced 
cytotoxicity and, therefore, this molecular mechanism could regulate the resistance to PF, possibly 






Figure 20. Effect of PF in combination with PD98 on U87MG cells viability.Cells were cultured with control media or 
pretreated in the absence or presence of 10 μM PD98 1 h prior to treatment with10 µM PF or 10 μM PD98, as indicated. 
Cells viability was assessed after 48 and 72 h of treatment by MTT assay. The results are expressed as a percentage of 
viable cells with respect to control untreated cells and presented as means ± SD of three independent experiments. 
Asterisks represent statistical significance determined by Student’s t test (*p < 0.05, **p < 0.01 vs PF-treated cells;  
#
p < 0.05; 
##
p < 0.01 vs PD98-treated cells). 
 
5.13 Effect of Perifosine in combination with D609 on U87MG cells viability 
 
Since we demonstrated that PF is able to reduce the SM level in U87MG cells acting through SMS, 
we wonder if this effect could be part of the cytotoxic mechanism of PF. To this purpose, we 
evaluated the effect of a SMS inhibitor, D609, in the absence or presence of PF on U87MG cells 
viability. As shown in Fig. 21, D609 treatment induced a decrease of cell viability of about 25% and 
19% at 48 and 72 hours, respectively, compared to control cells. Moreover, the treatment with PF 
plus D609 further reduced the viability of cells treated only with PF by about 28% and that of cells 
treated only with D609 by about 27% at 48 hours. Furthermore, treatment with PF combined with 
D609 induced a significantly decrease of cell viability by about 18% compared to cells treated only 
with PF and by about 41% compared to D609-treated cells at 72 hours of treatment. These results 
indicated that the inhibition of SM synthesis is involved in the cytotoxic effects of PF. However, 






Figure 21. Effect of PF in combination with D609 on U87MG cells viability. Cells were cultured with control media or 
pretreated in the absence or presence of 80 μM D609 2 h prior to treatment with10 µM PF or 80 μM D609, as indicated. 
Cells viability was assessed after 48 and 72 h of treatment by MTT assay. The results are expressed as a percentage of 
viable cells with respect to control untreated cells and presented as means ± SD of three independent experiments. 
Asterisks represent statistical significance determined by Student’s t test (*p < 0.05; **p < 0.01 vs PF-treated cells;  
#
p < 0.05; 
##
p < 0.01 vs D609-treated cells). 
 
5.14 Role of gangliosides in Perifosine-induced toxicity in U87MG cells 
 
The evidence that PF significantly increased the levels of endogenous gangliosides stimulated us to 
analyze whether the inhibition of gangliosides synthesis might be able to modulate U87MG cells 
death by preventing the cytotoxic effect of PF. 
To inhibit the synthesis of gangliosides and, as a consequence, their total amount in the cells, we 
inhibited the synthesis of GlcCer, the first GSL in the metabolic pathway for the synthesis of 
complex GSLs, using two different inhibitors of GCS: PPMP and PDMP. In particular, we 
evaluated the effect of PF on U87MG cells viability in the absence or presence of PPMP and 
PDMP, for 48 and 72 hours. As shown in Fig. 22, PPMP and PDMP alone did not induce cytotoxic 
effects by themselves, but they were able to reduce the cytotoxic effect of PF by inducing an 
increase in viable cell number of about 28% and 24% respectively at 48 hours of treatment and of 
about 31% and 42% respectively at 72 hours of treatment compared to cells treated only with PF. 
Taken together, these results indicate that the co-treatment of PF and PPMP or PDMP rendered 






Figure 22. Effect of PF in combination with PPMP or PDMP on U87MG cells viability. Cells were cultured with 
control media or pretreated in the absence or presence of 5 μM PPMP or 10 μM PDMP 2 h prior to treatment with 10 
µM PF, 5 μM PPMP or 10μM PDMP, as indicated. Cells viability was assessed after 48 and 72 h of treatment by MTT 
assay. The results are expressed as a percentage of viable cells with respect to control untreated cells and presented as 
means ± DS of three independent experiments. Asterisks represent statistical significance determined by Student’s t test 






GBM is the most frequent and aggressive malignant tumor of the CNS in adults. Despite decades of 
experimentation to improve the outcome of patients with GBM, this type of neoplasm remains the 
most lethal one. Therefore, the need to test different and new agents for efficacy and safety is urgent 
(Rich and Bigner, 2004; Wen and Kesari, 2008). PF, a relatively new compound belonging to the 
class of APLs, is a promising candidate for cancer chemotherapy, thanks to its rather unique 
mechanism of action. Indeed, unlike classical anti-cancer drugs, PF targets the cell membranes 
rather than the DNA (van Blitterswijk and Verheij, 2013). PF exhibits a potent antineoplastic 
activity against a multitude of cancer cell lines and different tumor models and is currently 
employed in a great number of phase II clinical trials (Fensterle et al., 2014; Gills and Dennis, 
2009). PF can induce apoptosis and/or cell growth arrest in tumor cells, with molecular mechanisms 
still to be elucidated. Different primary targets have been linked to its anticancer activity, even if 
inhibition of Akt seems to be the most important one. The survival signaling pathway PI3K/Akt, 
which is frequently up-regulated in GBM cells, is considered one of the most promising targets for 
tumor therapy (van Blitterswijk and Verheij, 2013). However, PF can induce also Akt-independent 
effects and the contribution of Akt inhibition to the clinical activity of PF remains to be assessed 
(Fensterle et al., 2014; Gills and Dennis, 2009). PF can interfere with the metabolism and transport 
of membrane lipids and/or the enrichment of PF in cell membranes can directly induce a 
biophysical disturbance of cell membranes, resulting in alteration of membrane lipid turnover and 
membrane associated signaling events (including Akt signaling), leading ultimately to cell death 
(Marco et al., 2014). However, the details of the PF mechanisms of action are still unclear, and this 
agent has not been studied fully in GBM cells. Our study provides a contribution to this complex 
field. 
 
First, since PTEN plays a critical role in regulating Akt activity, we examined the effects of PF on 
cell survival in three human GBM cell lines (T98G, CCF-STTG1 and U87MG), characterized by a 
different mutation status of PTEN. The PI3K/Akt signaling pathway, which has a crucial role in cell 
proliferation and  survival (Osaki et al., 2004), is frequently upregulated in gliomas through several 
mechanisms, and is significantly associated with increased tumor grade, decreased levels of 
apoptosis, and adverse clinical outcome in human gliomas (Chakravarti et al., 2004). Our results 
demonstrated that PF inhibits cell viability in a dose-dependent manner in all GBM cell lines (Fig. 
6). Moreover, comparison of the cell lines suggests that the sensitivity to PF was not correlated to 
PTEN mutation status and so to basal levels of p-Akt. These findings are consistent with a previous 
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report showing that PF affects cell viability in lung cancer cells independently of PTEN mutation 
status (Elrod et al., 2007). Furthermore, we evaluated if PF reduces Akt phosphorylation in our 
GBM cell lines upon serum stimulation. As expected, we obtained that PF promotes a decrease of 
p-Akt levels in a time-dependent manner, with a similar trend in all the studied cells (Fig. 7). These 
results are in agreement with several other studies showing that PF in different tumor cell lines 
(even in some GBM cell lines) is able to downregulate not only endogenous active Akt, but also 
serum and growth factor-stimulated Akt (de la Pena et al., 2006; Gills and Dennis, 2009; Zhang et 
al., 2007a). In parallel, we found that LY29, a potent inhibitor of PI3K (Knight, 2010), induces an 
almost complete inhibition of Akt after only 1 hour of treatment in the same GBM cell lines (Fig. 
7). We consequently wonder if PF is still able to modulate cell viability of U87MG cells exposed to 
LY29. Our data demonstrated that, even in that condition, namely when Akt is completely inhibited, 
PF is able to exert further cytotoxic effects, indicating that its action is not solely due to Akt 
inhibition (Fig. 8). 
Accumulating literature indicates that PF could affect cell membrane lipid metabolism and, 
consequently, cell membranes composition and functionality (Fensterle et al., 2014). In several 
tumor cell lines it has been shown that PF inhibits the rate limiting step of PC synthesis, which is 
catalyzed by CT enzyme, inducing cellular stress and subsequently apoptosis in rapidly 
proliferating cells. However, the mechanism by which PC induces cells death is still unclear. PC is 
the donor of phosphocholine in the reaction catalyzed by the enzyme SMS (Diringer et al., 1972; 
Riboni et al., 1997). In accordance with the precursor-product relationship, the inhibition of the PC 
biosynthesis may also affect the SM biosynthesis from PC and Cer and, as a consequence, may 
induce an accumulation of the last pro-death lipid. Based on these findings, we examined whether 
PF is able to inhibit PC and SM biosynthesis in U87MG cells. We found that when using 
radiolabeled choline as exogenous substrate, exposure of U87MG cells to PF produced a marked 
inhibition of PC and SM synthesis (Fig. 9). However, even if the PC biosynthesis was reduced, it 
seems not to be a limiting factor for SM synthesis. Since inhibition of SM biosynthesis should result 
in increased Cer levels, we investigated the effect of PF on Cer metabolism performing short time 
pulse experiments in U87MG cells by administering to cells tritiated Sph as Cer precursor. We 
found that the utilization of newly synthesized Cer was reduced in cell exposed to PF mainly for the 
biosynthesis of SM and, apparently, also for the biosynthesis of GlcCer and LacCer, without 
altering the process of Cer synthesis (Fig. 10). Of interest, in a previous study it has been 
demonstrated that U87MG cells, observed by transmission electron microscopy after exposure to 
PF or other ALPs, showed many enlarged Golgi cisternae (Rios-Marco et al., 2013). Since the 
biosynthesis of SM and GlcCer take place at the Golgi level, we could assume that PF could disturb 
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the Golgi membrane with an impact on SMS and GCS activities. Our results, obtained from SMS 
and GCS activity assays both in cell culture and cell-free, indicated that PF affects SMS activity 
without directly interact with the enzyme, while GCS activity is preserved in the same condition 
(Fig. 11). This discrepancy could be due to the different localization of the enzymes within the 
Golgi apparatus and the different orientation of their catalytic site, that is luminal for SMS and 
cytoplasmic for GCS (Schweizer et al., 1994). Based on these findings, we then assessed in U87MG 
cells the endogenous levels of PLs and gangliosides, as important functional component of cell 
membranes. We found that PF induced a decrease in the total PLs/protein ratio accompanied by a 
change in the PLs pattern. Indeed, PF-treated cells were poorer in PC, SM, and PS, and richer in PE 
than untreated cells (Fig. 12). Surprisingly, PF induces an about 60% increase of endogenous 
gangliosides levels compared to untreated cells (Fig. 13), indicating that the reduction of GlcCer 
and LacCer observed in metabolic experiments is not due to the inhibition of their biosynthesis, but 
rather to their rapid utilization for the synthesis of more complex GSLs. These findings indicate that 
PF profoundly alters membrane lipid metabolism and content and this could be the main mechanism 
by which it induces cell death. Analyzing the mechanism of PF-induced cells death in U87MG 
cells, we found that PF induces autophagy, while apoptosis was undetectable (Figs. 14 and 15). This 
results was confirmed in the other two GBM cell lines studied, indicating that this could be a 
general response of GBM cells to PF (Fig. 14). The role of autophagy in cancer therapy is still 
controversial. It may be the mechanism by which an agent effects cell killing (autophagic cell death 
or type II programmed cell death) or a tumor cell survival mechanism activated after cancer 
treatment. When autophagy is protective, its suppression would reduce cell viability, probably by 
accelerating entry into other forms of cell death (Wu et al., 2012). We demonstrated that, in 
U87MG cells, PF-induced autophagy requires ERK activity (Figs. 18 and 19). Inhibition of the 
MAPK pathway suppresses PF-induced autophagy and results in enhanced cytotoxicity (Figs. 19 
and 20). In line with our results, previous studies reported that PF induces protective autophagy and 
confirmed that autophagy prevention is able to significantly enhance PF-induced anti-cancer 
efficiency (Fu et al., 2009; Qin et al., 2013; Sun, 2010; Tong et al., 2012). In particular, Fu et al. 
showed that PF induces autophagy in human lung cancer cell lines by inhibiting the Akt/mTOR 
signaling pathway (Fu et al., 2009). As regard U87MG cell line, conflicting data have been reported 
showing that PF may induce autophagy (Qin et al., 2013) through the same mechanism reported by 
Fu et al. or may be inhibitory in the late stages of autophagy, blocking the autophagic flux (Rios-
Marco et al., 2015). To the best of our knowledge, we are the first showing that ERK activity is 
required for PF-induced autophagy. Our data contrast with previous ﬁndings showing that ERK was 
not affected by PF-treatment in U87MG cells (Qin et al., 2013), but agree with those of other 
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studies in which it has been reported that PF could induce ERK activation in different cells lines 
(Hideshima et al., 2006; Hou et al., 2014; Leleu et al., 2007). In addition, it has been reported that 
other drugs, such as curcumin and the natural products triterpenoid B-group soyasaponins induced 
autophagy by inhibiting Akt signaling and enhancing ERK activity (Aoki et al., 2007; Ellington et 
al., 2006). The final outcome of autophagy, in terms of survival or death of the cells, would depend 
on specific cellular setting. In U87MG cells exposed to PF we found a time-dependent increase of 
cells with an irregular shape and that are giant and multinucleated (Figs. 14, 16, and 17). These 
morphological changes resemble those described for mitotic catastrophe. Mitotic catastrophe is a 
mode of cell death that occurs in response to several anticancer agents, which originates from 
mitotic perturbations detected during mitosis and always accompanied by mitotic arrest (Portugal et 
al., 2010). Ríos-Marco at al. demonstrated that the exposure of U87MG cells to PF and others APLs 
induces G2/M phase cell-cycle arrest (Rios-Marco et al., 2013). In particular, ALPs decreased the 
phosphorylation status of Tyr15 in cdc2 kinase protein, which governs the activity of the 
cdc2/cyclin B1 complex (responsible for the onset of mitosis), indicating that they provoke mitotic 
arrest (Rios-Marco et al., 2013). Taken together, these findings indicate that PF in U87MG cells 
could induce cell death through mitotic catastrophe. 
As we reported above, lipid membrane microdomains are important signaling platforms whose 
structure and functionality are sensitive to membrane lipid composition (Sonnino and Prinetti, 
2010). Since we demonstrated that PF induce a pronounced alteration of lipid membrane 
metabolism and content, these alterations could well affect lipid microdomain functionality and 
ultimately induce cell death. In particular, we showed that PF affects not only PC biosynthesis, but 
also glycerophospholipids and SLs ones. SLs are particularly abundant in the plasma membrane, 
where SM and GSLs represent the major SLs, displaying an asymmetric or polarized distribution, 
and play important roles in the regulation of membrane fluidity and sub-domain structures (Sonnino 
and Prinetti, 2010). We demonstrated that SM and GSLs were both affected by PF. Moreover, it has 
been shown that SM biosynthesis by SMS1 in the Golgi apparatus is crucial for new lipid 
microdomains formation and for subsequent cycling of these structures towards and from the 
plasma membrane (Ikonen, 2001; Tafesse et al., 2006; van Blitterswijk et al., 2003). Mimicking the 
effect of PF on SMS using the D609 compound in U87MG cells, we found a reduction in cell 
viability increased in combination with PF treatment (Fig. 21). This result indicates that inhibition 
of SM synthesis is part of the cytotoxic mechanism of PF, but additional molecular mechanisms are 
involved in its action. One can assume that the cytotoxic effect induced by inhibiting SMS could be 
also due to the production of Cer at the ER level. However, even if we demonstrated in metabolic 
studies that PF induces a modest increase in the Cer levels, Qui at al. showed that the endogenous 
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Cer content is only slightly enhanced after PF exposure (Qin et al., 2013) and, coherently, Ríos-
Marco at al. demonstrated that PF and other APLs failed to provoke ER stress in the U87MG cell 
line (Rios-Marco et al., 2015). These findings indicate that other mechanisms, such as that involved 
in membrane functionality, are most probably involved in PF-induced cell death. Intriguingly, Ríos-
Marco et al. showed that PF and other ALPs induce a deregulation of cholesterol homeostasis that 
ultimately leads to an accumulation of free cholesterol within the cell and, in particular, in 
membrane microdomains such as lipid rafts, disrupting their function. However, in U87MG cells 
they reported an accumulation of free cholesterol in the cytoplasmic compartment, but not at the 
plasma membrane level (Rios-Marco et al., 2013). Herein, we showed that PF enormously enhances 
gangliosides endogenous content (Fig. 13). Gangliosides reside mostly in the outer leaflet of the 
plasma membranes, where they cluster to forms GSLs-enriched microdomains, which provide a 
microenvironment for reciprocal interactions between lipids and protein molecules involved in the 
control of signal transduction (Sonnino and Prinetti, 2010). GSLs show a specific distribution on 
the membrane for each cell type, which can vary with differentiation and neoplastic transformation 
(Huwiler et al., 2000; Kaucic et al., 2001; Segui et al., 2006). In U87MG cells, we found that 
inhibiting the first step in the metabolic pathway of the synthesis of complex GSLs, including 
gangliosides, by the use of two different GCS inhibitors (PPMP and PDMP), was paralleled by an 
increase in cell resistance to the cytotoxic effect of PF (Fig. 22). Recently, an interested study 
reported that gangliosides may play a role in the localization of the APL Edelfosine to lipid rafts, 
due to its stronger affinity for gangliosides than for SM (Hac-Wydro and Dynarowicz-Latka, 2010). 
Since Edelfosine is structurally related to PF, this could rise the hypothesis that also PF, as well as 
other APLs, have a high affinity to ganglosides. Consequently, gangliosides could have a role also 
in APLs uptake. To the best of our knowledge, we are the first showing that gangliosides are major 
player in mediating the cytotoxic action of PF. 
 
In conclusion, PF treatment in GBM cells results in a complex network of effects where the 
alteration of the metabolism and content of membrane-lipid components (and maybe their related 
secondary messengers) seems to play a key role in determining cell death. In this scenario, 
gangliosides are the main players. This study indicates that PF is decisive in its target to fight GBM 
cells, this representing a critical push to study new aspects in its cellular mechanisms, implying PF 
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